<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41031479</PMID><DateRevised><Year>2025</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1522-726X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography &amp; Interventions</Title><ISOAbbreviation>Catheter Cardiovasc Interv</ISOAbbreviation></Journal><ArticleTitle>Drug-Coated Balloon Versus Drug-Eluting Stent for De Novo Lesions of Large Coronary Arteries: A Systematic Review and Meta-Analysis of Angiographic and Clinical Outcomes.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/ccd.70223</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Efficacy of drug-coated balloons (DCBs) has been established in the treatment of in-stent restenosis and small vessel coronary artery disease, while utility in large-vessel de novo lesions remains controversial.</AbstractText><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">We sought to study the angiographic and clinical outcomes after treatment of large vessel de novo coronary lesions with DCB versus drug-eluting stent (DES).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We systematically searched electronic databases through March 2025 for relevant studies. Outcomes were compared using random effects modeling for summary estimates. We performed subgroup analyses by study design.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Our analysis included 16 studies (eight randomized controlled trials and eight observational) with 9745 patients. Follow-up duration was 17&#x2009;&#xb1;&#x2009;8 months for DCB and 16&#x2009;&#xb1;&#x2009;4 months for DES. While acute gain was significantly lower with DCB (MD&#x2009;=&#x2009;-0.45, 95% CI: -0.63 to -0.26; p&#x2009;&lt;&#x2009;0.00001; I&#xb2;&#x2009;=&#x2009;74%), no significant differences were observed in late lumen loss (MD&#x2009;=&#x2009;-0.03, 95% CI: -0.09 to 0.04; p&#x2009;=&#x2009;0.47; I&#xb2; = 47%) or binary restenosis (RR&#x2009;=&#x2009;2.22, 95% CI: 0.94 to 5.24; p&#x2009;=&#x2009;0.07; I&#xb2; = 13%). Clinically, there was no significant difference between DCB and DES in target lesion failure and overall major adverse cardiac events, and this was consistent regardless of the study design (randomized vs. observational).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Compared with DES, treatment with DCB yields a less optimal immediate angiographic result but comparable clinical outcomes in patients with de novo lesions of large coronary arteries.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hassan</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Suez Medical Complex, Ministry of Health and Population, Suez, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mansour</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Al-Azhar University, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elkasaby</LastName><ForeName>Mohamed Hamouda</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Al-Azhar University, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramadan</LastName><ForeName>Shrouk</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-6776-883X</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Ain Shams University, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nabil</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9605-1539</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suwannasom</LastName><ForeName>Pannipa</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saad</LastName><ForeName>Marwan</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2280-8030</Identifier><AffiliationInfo><Affiliation>Lifespan Cardiovascular Institute and Warren Alpert Medical School, Brown University, Providence, Rhode Island, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Winter</LastName><ForeName>Robbert J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Cardiology Department, Amsterdam UMC, University of Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hemetsberger</LastName><ForeName>Rayyan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Internal Medicine II, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdelghani</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6949-8749</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Al-Azhar University, Cairo, Egypt.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiology Department, Amsterdam UMC, University of Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiology Unit, Department of Internal Medicine, Sohar Hospital, Sohar, Oman.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>The authors received no specific funding for this work.</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Catheter Cardiovasc Interv</MedlineTA><NlmUniqueID>100884139</NlmUniqueID><ISSNLinking>1522-1946</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">drug&#x2010;coated balloon</Keyword><Keyword MajorTopicYN="N">drug&#x2010;eluting stent</Keyword><Keyword MajorTopicYN="N">large de novo coronary artery lesions</Keyword><Keyword MajorTopicYN="N">meta&#x2010;analysis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>5</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41031479</ArticleId><ArticleId IdType="doi">10.1002/ccd.70223</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>A. Hassan, A. M. Amin, A. F. Gadelmawla, et al., &#x201c;Comparative Effectiveness of Ultrathin vs. Standard Strut Drug&#x2010;Eluting Stents: Insights From a Large&#x2010;Scale Meta&#x2010;Analysis With Extended Follow&#x2010;Up,&#x201d; European Journal of Medical Research 29, no. 1 (July 2024): 388.</Citation></Reference><Reference><Citation>M. V. Madhavan, A. J. Kirtane, B. Redfors, et al., &#x201c;Stent&#x2010;Related Adverse Events &gt;&#x2009;1 Year After Percutaneous Coronary Intervention,&#x201d; Journal of the American College of Cardiology 75, no. 6 (February 2020): 590&#x2013;604.</Citation></Reference><Reference><Citation>Y. Sotomi, P. Suwannasom, E. Tenekecioglu, et al., &#x201c;Differential Aspects Between Cobalt&#x2010;Chromium Everolimus Drug&#x2010;Eluting Stent and Absorb Everolimus Bioresorbable Vascular Scaffold: From Bench to Clinical Use,&#x201d; Expert Review of Cardiovascular Therapy 13, no. 10 (October 2015): 1127&#x2013;1145.</Citation></Reference><Reference><Citation>S. Kufner, M. Joner, A. Thannheimer, et al., &#x201c;Ten&#x2010;Year Clinical Outcomes From a Trial of Three Limus&#x2010;Eluting Stents With Different Polymer Coatings in Patients with Coronary Artery Disease: Results From the ISAR&#x2010;TEST 4 Randomized Trial,&#x201d; Circulation 139, no. 3 (January 2019): 325&#x2013;333.</Citation></Reference><Reference><Citation>T. Pilgrim, R. Piccolo, D. Heg, et al., &#x201c;Ultrathin&#x2010;Strut, Biodegradable&#x2010;Polymer, Sirolimus&#x2010;Eluting Stents Versus Thin&#x2010;Strut, Durable&#x2010;Polymer, Everolimus&#x2010;Eluting Stents for Percutaneous Coronary Revascularisation: 5&#x2010;Year Outcomes of the BIOSCIENCE Randomised Trial,&#x201d; Lancet 392, no. 10149 (September 2018): 737&#x2013;746.</Citation></Reference><Reference><Citation>M. G. Kong, J. K. Han, J. H. Kang, et al., &#x201c;Clinical Outcomes of Long Stenting in the Drug&#x2010;Eluting Stent Era: Patient&#x2010;Level Pooled Analysis From the GRAND&#x2010;DES Registry,&#x201d; EuroIntervention 16, no. 16 (March 2021): 1318&#x2013;1325.</Citation></Reference><Reference><Citation>F. J. Sawaya, T. Lef&#xe8;vre, B. Chevalier, et al., &#x201c;Contemporary Approach to Coronary Bifurcation Lesion Treatment,&#x201d; JACC: Cardiovascular Interventions 9, no. 18 (September 2016): 1861&#x2013;1878.</Citation></Reference><Reference><Citation>R. V. Jeger, S. Eccleshall, W. A. Wan Ahmad, et al., &#x201c;Drug&#x2010;Coated Balloons for Coronary Artery Disease,&#x201d; JACC: Cardiovascular Interventions 13, no. 12 (June 2020): 1391&#x2013;1402.</Citation></Reference><Reference><Citation>R. V. Jeger, A. Farah, M. A. Ohlow, et al., &#x201c;Long&#x2010;Term Efficacy and Safety of Drug&#x2010;Coated Balloons Versus Drug&#x2010;Eluting Stents for Small Coronary Artery Disease (Basket&#x2010;Small 2): 3&#x2010;Year Follow&#x2010;Up of a Randomised, Non&#x2010;Inferiority Trial,&#x201d; Lancet 396, no. 10261 (November 2020): 1504&#x2013;1510.</Citation></Reference><Reference><Citation>S. Y. Lee, Y. K. Cho, S. W. Kim, et al., &#x201c;Clinical Results of Drug&#x2010;Coated Balloon Treatment in a Large&#x2010;Scale Multicenter Korean Registry Study,&#x201d; Korean Circulation Journal 52, no. 6 (2022): 444.</Citation></Reference><Reference><Citation>C. Gobbi, F. Giangiacomi, I. Merinopoulos, et al., &#x201c;Drug Coated Balloon Angioplasty for De Novo Coronary Lesions in Large Vessels: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Scientific Reports 15, no. 1 (February 2025): 4921.</Citation></Reference><Reference><Citation>R. Caminiti, G. Vizzari, A. Ielasi, et al., &#x201c;Drug&#x2010;Coated Balloon Versus Drug&#x2010;Eluting Stent for Treating De Novo Large Vessel Coronary Artery Disease: A Systematic Review and Meta&#x2010;Analysis of 13 Studies Involving 2888 Patients,&#x201d; Clinical Research in Cardiology 114 (July 2024): 978&#x2013;990, https://doi.org/10.1007/s00392-024-02481-8.</Citation></Reference><Reference><Citation>J. L. Jiang, Q. J. Huang, and M. H. Chen, &#x201c;Efficacy and Safety of Drug&#x2010;Coated Balloon for De Novo Lesions of Large Coronary Arteries: Systematic Review and Meta&#x2010;Analysis of Randomized Controlled Trials,&#x201d; Heliyon 10, no. 3 (February 2024): e25264.</Citation></Reference><Reference><Citation>Z. Ma, K. Liu, Y. Hu, X. Hu, B. Wang, and Z. Li, &#x201c;Comparison Between Drug&#x2010;Coated Balloon and Stents in Large De Novo Coronary Artery Disease: A Systematic Review and Meta&#x2010;Analysis of RCT Data,&#x201d; Cardiovasc Drugs Ther [Internet] 39, no. 3 (January 2025): 677&#x2013;686, https://doi.org/10.1007/s10557-024-07548-2.</Citation></Reference><Reference><Citation>A. Abdel&#x2010;Salam and K. Eyres, &#x201c;Effects of Tourniquet During Total Knee Arthroplasty. A Prospective Randomised Study,&#x201d; Journal of Bone and Joint Surgery. British Volume 77&#x2013;B, no. 2 (March 1995): 250&#x2013;253.</Citation></Reference><Reference><Citation>J. J. Coughlan and A. Kastrati, &#x201c;Small Coronary Vessel Size: A Great Need for a Standardized Definition,&#x201d; Journal of the Society for Cardiovascular Angiography &amp; Interventions 1, no. 5 (September 2022): 100428.</Citation></Reference><Reference><Citation>X. F. Gao, X. Q. Kong, G. F. Zuo, Z. M. Wang, Z. Ge, and J. J. Zhang, &#x201c;Intravascular Ultrasound&#x2010;Guided Versus Angiography&#x2010;Guided Percutaneous Coronary Intervention: Evidence From Observational Studies and Randomized Controlled Trials,&#x201d; US Cardiology Review 14 (April 2020): e03.</Citation></Reference><Reference><Citation>L. Mauri, E. J. Orav, and R. E. Kuntz, &#x201c;Late Loss in Lumen Diameter and Binary Restenosis for Drug&#x2010;Eluting Stent Comparison,&#x201d; Circulation 111, no. 25 (June 2005): 3435&#x2013;3442.</Citation></Reference><Reference><Citation>T. Onishi, Y. Onishi, I. Kobayashi, and Y. Sato, &#x201c;Late Lumen Enlargement After Drug&#x2010;Coated Balloon Angioplasty for De Novo Coronary Artery Disease,&#x201d; Cardiovascular Intervention and Therapeutics 36, no. 3 (July 2021): 311&#x2013;318.</Citation></Reference><Reference><Citation>G. Zenunaj, L. Traina, P. Acciarri, et al., &#x201c;Primary Drug&#x2010;Coated Balloon Versus Drug&#x2010;Eluting Stent for Native Atherosclerotic Femoropopliteal Lesions: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Annals of Vascular Surgery 92 (May 2023): 294&#x2013;303.</Citation></Reference><Reference><Citation>J. A. C. Sterne, J. Savovi&#x107;, M. J. Page, et al., &#x201c;RoB 2: A Revised Tool for Assessing Risk of Bias in Randomised Trials,&#x201d; BMJ 366 (August 2019): l4898.</Citation></Reference><Reference><Citation>A. Stang, &#x201c;Critical Evaluation of the Newcastle&#x2010;Ottawa Scale for the Assessment of the Quality of Nonrandomized Studies in Meta&#x2010;Analyses,&#x201d; European Journal of Epidemiology 25, no. 9 (September 2010): 603&#x2013;605.</Citation></Reference><Reference><Citation>C. Gobbi, F. Giangiacomi, G. Pasero, et al., &#x201c;Efficacy and Safety of Sirolimus&#x2010;Coated Balloon Angioplasty in De Novo Lesions in Large Coronary Vessels: A Propensity Score&#x2010;Matched Study,&#x201d; Catheterization and Cardiovascular Interventions 105, no. 4 (March 2025): 861&#x2013;869.</Citation></Reference><Reference><Citation>C. Xingyou Cai, H. Xin Hong, W. Yuli Wang, Li Yafei Li, and Xu Guidong Xu, &#x201c;Drug&#x2010;Coated Balloon in the Treatment of Coronary Artery De&#x2010;Novo Large Lesionsangiography,&#x201d; Cellular and Molecular Biology 70, no. 4 (April 2024): 196&#x2013;201.</Citation></Reference><Reference><Citation>C. Gao, X. He, F. Ouyang, et al., &#x201c;Drug&#x2010;Coated Balloon Angioplasty with Rescue Stenting Versus Intended Stenting for the Treatment of Patients with De Novo Coronary Artery Lesions (REC&#x2010;CAGEFREE I): an Open&#x2010;Label, Randomised, Non&#x2010;Inferiority Trial,&#x201d; Lancet 404, no. 10457 (September 2024): 1040&#x2013;1050.</Citation></Reference><Reference><Citation>J. Goto, T. Niizeki, T. Iwayama, T. Sasaki, and M. Watanabe, &#x201c;One&#x2010;Year Outcome of Drug&#x2010;Coated Balloon Vs. Drug&#x2010;Eluting Stent in Patients Undergoing Initial Percutaneous Coronary Intervention (PCI) for De Novo Lesion,&#x201d; Cureus [Internet] 16, no. 3 (March 2024): e56346, https://www.cureus.com/articles/236464-one-year-outcome-of-drug-coated-balloon-vs-drug-eluting-stent-in-patients-undergoing-initial-percutaneous-coronary-intervention-pci-for-de-novo-lesion.</Citation></Reference><Reference><Citation>K. Zhao, Q. Guo, Z. Zhao, et al., &#x201c;Clinical Value of Drug&#x2010;Coated Balloon Versus Second&#x2010;Generation Drug&#x2010;Eluting Stent for De Novo Lesions in Large Coronary Arteries: Insights From the Real World,&#x201d; BMC Cardiovasc Disord [Internet] 24, no. 1 (December 2024): 697, https://doi.org/10.1186/s12872-024-04386-w.</Citation></Reference><Reference><Citation>I. Merinopoulos, T. Gunawardena, N. Corballis, et al., &#x201c;Assessment of Paclitaxel Drug&#x2010;Coated Balloon Only Angioplasty in STEMI,&#x201d; JACC: Cardiovascular Interventions 16, no. 7 (April 2023): 771&#x2013;779.</Citation></Reference><Reference><Citation>I. Merinopoulos, T. Gunawardena, N. Corballis, et al., &#x201c;Paclitaxel Drug&#x2010;Coated Balloon&#x2010;Only Angioplasty for De Novo Coronary Artery Disease in Elective Clinical Practice,&#x201d; Clinical Research in Cardiology 112, no. 9 (September 2023): 1186&#x2013;1193.</Citation></Reference><Reference><Citation>C. Li, X. Ding, L. Wang, et al., &#x201c;Feasibility and Safety of Drug&#x2010;Coated Balloon&#x2010;Only Angioplasty for De Novo Ostial Lesions of the Left Anterior Descending Artery: Two&#x2010;Center Retrospective Study,&#x201d; Front Cardiovasc Med [Internet] 9 (April 2022): 874394, https://doi.org/10.3389/fcvm.2022.874394/full.</Citation></Reference><Reference><Citation>R. V. Jeger, A. Farah, M. A. Ohlow, et al., &#x201c;Long&#x2010;Term Efficacy and Safety of Drug&#x2010;Coated Balloons Versus Drug&#x2010;Eluting Stents for Small Coronary Artery Disease (BASKET&#x2010;SMALL 2): 3&#x2010;Year Follow&#x2010;Up of a Randomised, Non&#x2010;Inferiority Trial,&#x201d; Lancet 396, no. 10261 (November 2020): 1504&#x2013;1510.</Citation></Reference><Reference><Citation>A. Farah, M. Elgarhy, M. A. Ohlow, et al., &#x201c;Efficacy and Safety of Drug&#x2010;Coated Balloons According to Coronary Vessel Size. A Report From the BASKET&#x2010;SMALL 2 Trial,&#x201d; Adv Interv Cardiol 18, no. 2 (2022): 122&#x2013;130.</Citation></Reference><Reference><Citation>H. Liu, Y. Zhao, Y. Lu, et al., &#x201c;The Drug Coated Balloon&#x2010;Only Strategy for Treatment of De Novo Left Main Coronary Artery Bifurcation Lesion: Stentless Strategy,&#x201d; Clinical and Applied Thrombosis/Hemostasis 28 (January 2022): 10760296221118489.</Citation></Reference><Reference><Citation>Z. Wang, Y. Yin, J. Li, et al., &#x201c;New Ultrasound&#x2010;Controlled Paclitaxel Releasing Balloon Vs. Asymmetric Drug&#x2010;Eluting Stent in Primary ST&#x2010;Segment Elevation Myocardial Infarction&#x2015;A Prospective Randomized Trial,&#x201d; Circulation Journal 86, no. 4 (March 2022): 642&#x2013;650.</Citation></Reference><Reference><Citation>X. Hao, D. Huang, Z. Wang, J. Zhang, H. Liu, and Y. Lu, &#x201c;Study on the Safety and Effectiveness of Drug&#x2010;Coated Balloons In Patients With Acute Myocardial Infarction,&#x201d; Journal of Cardiothoracic Surgery [Internet] 16, no. 1 (December 2021): 178, https://doi.org/10.1186/s13019-021-01525-8.</Citation></Reference><Reference><Citation>Y. Iwasaki, J. Koike, T. Ko, et al., &#x201c;Comparison of Drug&#x2010;Eluting Stents Vs. Drug&#x2010;Coated Balloon After Rotational Atherectomy for Severely Calcified Lesions of Nonsmall Vessels,&#x201d; Heart and Vessels 36, no. 2 (February 2021): 189&#x2013;199.</Citation></Reference><Reference><Citation>N. S. Vos, N. D. Fagel, G. Amoroso, et al., &#x201c;Paclitaxel&#x2010;Coated Balloon Angioplasty Versus Drug&#x2010;Eluting Stent in Acute Myocardial Infarction,&#x201d; JACC: Cardiovascular Interventions 12, no. 17 (September 2019): 1691&#x2013;1699.</Citation></Reference><Reference><Citation>N. Nishiyama, T. Komatsu, T. Kuroyanagi, et al., &#x201c;Clinical Value of Drug&#x2010;Coated Balloon Angioplasty for De Novo Lesions in Patients With Coronary Artery Disease,&#x201d; International Journal of Cardiology 222 (November 2016): 113&#x2013;118.</Citation></Reference><Reference><Citation>F. Nijhoff, P. Agostoni, A. Belkacemi, et al., &#x201c;Primary Percutaneous Coronary Intervention by Drug&#x2010;Eluting Balloon Angioplasty: The Nonrandomized Fourth Arm of the Deb&#x2010;Ami (Drug&#x2010;Eluting Balloon in St&#x2010;Segment Elevation Myocardial Infarction) Trial,&#x201d; supplement, Catheter Cardiovasc Interv [Internet] 86, no. S1 (October 2015): S34&#x2013;S44, https://doi.org/10.1002/ccd.26060.</Citation></Reference><Reference><Citation>L. Wang, X. Li, T. Li, L. Liu, H. Wang, and C. Wang, &#x201c;Novel Application of Drug&#x2010;Coated Balloons in Coronary Heart Disease: A Narrative Review,&#x201d; Frontiers in Cardiovascular Medicine 10 (March 2023): 1055274.</Citation></Reference><Reference><Citation>M. Lunardi, C. Zivelonghi, F. S. Van Den Brink, et al., &#x201c;Drug Eluting Balloon for the Treatment of Patients With Coronary Artery Disease: Current Perspectives,&#x201d; Cardiovascular Revascularization Medicine 19, no. 2 (March 2018): 215&#x2013;220.</Citation></Reference><Reference><Citation>S. P. Hoole and P. Bambrough, &#x201c;Recent Advances in Percutaneous Coronary Intervention,&#x201d; Heart 106, no. 18 (September 2020): 1380&#x2013;1386.</Citation></Reference><Reference><Citation>A. Habib and A. V. Finn, &#x201c;Endothelialization of Drug Eluting Stents and Its Impact on Dual Anti&#x2010;Platelet Therapy Duration,&#x201d; Pharmacological Research 93 (March 2015): 22&#x2013;27.</Citation></Reference><Reference><Citation>F. Kleber, D. Mathey, H. Rittger, and B. Scheller, &#x201c;How to Use the Drug&#x2010;Eluting Balloon: Recommendations by the German Consensus Group,&#x201d; EuroIntervention 7, no. K (May 2011): K125&#x2013;K128.</Citation></Reference><Reference><Citation>T. D. Gunawardena, N. Corballis, I. Merinopoulos, et al., &#x201c;Drug&#x2010;Coated Balloon Vs. Drug&#x2010;Eluting Stents for De Novo Unprotected Left Main Stem Disease: The SPARTAN&#x2010;LMS Study,&#x201d; Journal of Cardiovascular Development and Disease 10, no. 2 (February 2023): 84.</Citation></Reference><Reference><Citation>A. Y. Her, S. L. Yuan, E. J. Jun, et al., &#x201c;Drug&#x2010;Coated Balloon Treatment for Nonsmall De&#x2010;Novo Coronary Artery Disease: Angiographic and Clinical Outcomes,&#x201d; Coronary Artery Disease 32, no. 6 (September 2021): 534&#x2013;540.</Citation></Reference><Reference><Citation>Y. Lin, X. Sun, H. Liu, X. Pang, and S. Dong, &#x201c;Drug&#x2010;Coated Balloon Versus Drug&#x2010;Eluting Stent for Treating De Novo Coronary Lesions in Large Vessels: A Meta&#x2010;Analysis of Clinical Trials,&#x201d; Herz 46, no. 3 (June 2021): 269&#x2013;276.</Citation></Reference><Reference><Citation>Z. Ma, K. Liu, Y. Hu, X. Hu, B. Wang, and Z. Li, &#x201c;Comparison Between Drug&#x2010;Coated Balloon and Stents in Large De Novo Coronary Artery Disease: A Systematic Review and Meta&#x2010;Analysis of RCT Data,&#x201d; Cardiocasular Drugs and Therapy 39, (January 2025): 677&#x2013;686, https://doi.org/10.1007/s10557-024-07548-2.</Citation></Reference><Reference><Citation>R. W. Yeh, R. Shlofmitz, J. Moses, et al., &#x201c;Paclitaxel&#x2010;Coated Balloon Vs Uncoated Balloon for Coronary In&#x2010;Stent Restenosis: The AGENT IDE Randomized Clinical Trial,&#x201d; Journal of the American Medical Association 331, no. 12 (March 2024): 1015.</Citation></Reference><Reference><Citation>A. Latib, N. Ruparelia, A. Menozzi, et al., &#x201c;3&#x2010;Year Follow&#x2010;Up of the Balloon Elution and Late Loss Optimization Study (BELLO),&#x201d; JACC: Cardiovascular Interventions 8, no. 8 (July 2015): 1132&#x2013;1134.</Citation></Reference><Reference><Citation>B. Cortese, G. Di Palma, M. G. Guimaraes, et al., &#x201c;Drug&#x2010;Coated Balloon Versus Drug&#x2010;Eluting Stent for Small Coronary Vessel Disease,&#x201d; JACC: Cardiovascular Interventions 13, no. 24 (December 2020): 2840&#x2013;2849.</Citation></Reference><Reference><Citation>C. Yerasi, B. C. Case, B. J. Forrestal, et al., &#x201c;Risk of Mortality With Paclitaxel Drug&#x2010;Coated Balloon in De Novo Coronary Artery Disease,&#x201d; Cardiovascular Revascularization Medicine 21, no. 4 (April 2020): 549&#x2013;555.</Citation></Reference><Reference><Citation>T. Yamamoto, T. Ishii, and A. Ishida, &#x201c;Impact of Post Physiological Assessment After Treatment for De Novo Coronary Lesions Using Drug&#x2010;Coated Balloons,&#x201d; International Journal of Cardiology 363 (September 2022): 11&#x2013;19.</Citation></Reference><Reference><Citation>T. Asano, P. W. Serruys, C. Collet, et al., &#x201c;Angiographic Late Lumen Loss Revisited: Impact on Long&#x2010;Term Target Lesion Revascularization,&#x201d; European Heart Journal 39, no. 36 (September 2018): 3381&#x2013;3389.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">41031166</PMID><DateCompleted><Year>2025</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in pharmacology</Title><ISOAbbreviation>Front Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Persimmon leaf extract in dyslipidemia: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>1572678</StartPage><MedlinePgn>1572678</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1572678</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2025.1572678</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="UNASSIGNED">This study aims to evaluate the effects of the combined application of <i>Diospyros kaki</i> Thunb. [Ebenaceae; <i>Kaki folium</i>] (Persimmon leaf) extract on lipid profiles in adults and to explore its potential role in preventing and treating lipid disorders and associated diseases, including common comorbidities such as cardiovascular and cerebrovascular diseases, as well as medication-induced dyslipidemia.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">From the inception of the database to 1 November 2024, we retrieved randomized controlled trials (RCTs) from eight English and Chinese databases.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 704 articles were retrieved, from which 16 studies were selected for inclusion in the systematic review and meta-analysis. These studies encompassed 1,572 patients, with 790 assigned to the treatment group and 782 to the control group. Among the dyslipidemia patients included in the study, the most common comorbidities were coronary artery disease, hypertension, ischemic cerebrovascular disease, and dyslipidemia induced by olanzapine, among others. Compared with the control group, the use of combined Persimmon leaf extract (PLE) significantly reduced total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) levels, while demonstrating a certain degree of improvement in high-density lipoprotein cholesterol (HDL-C) levels.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">PLE has been shown to be effective in improving blood lipid profiles in patients, suggesting its potential for widespread clinical application. However, the significant heterogeneity observed across existing studies, coupled with the frequent occurrence of methodological flaws, emphasizes the need for well-designed clinical trials with large sample sizes and extended follow-up periods.</AbstractText><AbstractText Label="SYSTEMATIC REVIEW REGISTRATION" NlmCategory="UNASSIGNED">https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=562090, identifier CRD42024562090.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Dong, Chang, Wang, Zhou, Wang, Wang, Sun, Liao, Cui and Guo.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Dong</LastName><ForeName>Chenxuan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Chang</LastName><ForeName>Tianying</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>EBM Office, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaoli</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pathology, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lisha</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaodan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Xing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Clinical Basic Medicine of Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Yingzi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>EBM Office, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Jiajuan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>President's Office, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pharmacol</MedlineTA><NlmUniqueID>101548923</NlmUniqueID><ISSNLinking>1663-9812</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Diospyros kaki Thunb. [Ebenaceae, Kaki folium]</Keyword><Keyword MajorTopicYN="N">dyslipidemia</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">persimmon leaf extract</Keyword><Keyword MajorTopicYN="N">systematic review</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>12</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>5</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41031166</ArticleId><ArticleId IdType="pmc">PMC12477231</ArticleId><ArticleId IdType="doi">10.3389/fphar.2025.1572678</ArticleId><ArticleId IdType="pii">1572678</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aradine E., Hou Y., Cronin C. A., Chaturvedi S. (2020). Current status of dyslipidemia treatment for stroke prevention. Curr. Neurol. Neurosci. Rep. 20 (8), 31. 10.1007/s11910-020-01052-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11910-020-01052-4</ArticleId><ArticleId IdType="pubmed">32572590</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnett D. K., Blumenthal R. S., Albert M. A., Buroker A. B., Goldberger Z. D., Hahn E. J., et al. (2019). 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American heart association task force on clinical practice guidelines. Circulation 140 (11), e596&#x2013;e646. 10.1161/cir.0000000000000678</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/cir.0000000000000678</ArticleId><ArticleId IdType="pmc">PMC7734661</ArticleId><ArticleId IdType="pubmed">30879355</ArticleId></ArticleIdList></Reference><Reference><Citation>Arvanitis M., Lowenstein C. J. (2023). Dyslipidemia. Ann. Intern Med. 176 (6), Itc81&#x2013;Itc96. 10.7326/aitc202306200</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/aitc202306200</ArticleId><ArticleId IdType="pubmed">37307585</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamin E. J., Blaha M. J., Chiuve S. E., Cushman M., Das S. R., Deo R., et al. (2017). Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation 135 (10), e146&#x2013;e603. 10.1161/cir.0000000000000485</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/cir.0000000000000485</ArticleId><ArticleId IdType="pmc">PMC5408160</ArticleId><ArticleId IdType="pubmed">28122885</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhargava S., de la Puente-Secades S., Schurgers L., Jankowski J. (2022). Lipids and lipoproteins in cardiovascular diseases: a classification. Trends Endocrinol. Metab. 33 (6), 409&#x2013;423. 10.1016/j.tem.2022.02.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2022.02.001</ArticleId><ArticleId IdType="pubmed">35370062</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatia H. S., Wandel S., Willeit P., Lesogor A., Bailey K., Ridker P. M., et al. (2024). Independence of lipoprotein(a) and low-density lipoprotein cholesterol-mediated cardiovascular risk: a participant-level meta-analysis. Circulation 151, 312&#x2013;321. 10.1161/circulationaha.124.069556</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circulationaha.124.069556</ArticleId><ArticleId IdType="pmc">PMC11771346</ArticleId><ArticleId IdType="pubmed">39492722</ArticleId></ArticleIdList></Reference><Reference><Citation>Butt M. S., Sultan M. T., Aziz M., Naz A., Ahmed W., Kumar N., et al. (2015). Persimmon (Diospyros kaki) fruit: hidden phytochemicals and health claims. Excli J. 14, 542&#x2013;561. 10.17179/excli2015-159</Citation><ArticleIdList><ArticleId IdType="doi">10.17179/excli2015-159</ArticleId><ArticleId IdType="pmc">PMC4817420</ArticleId><ArticleId IdType="pubmed">27047315</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardiovascular Disease Branch of the Chinese Medical Association Professional Committee of Cardiac Prevention and Rehabilitation C.A.o.R.M.C.P.C.o.t.C.G.a.G.S. (2020). Chinese guidelines for the primary prevention of cardiovascular diseases. Chin. J. Cardiol. 48 (12), 1000&#x2013;1038. 10.3760/cma.j.cn112148-20201009-00796</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.cn112148-20201009-00796</ArticleId><ArticleId IdType="pubmed">33355747</ArticleId></ArticleIdList></Reference><Reference><Citation>Carli M., Kolachalam S., Longoni B., Pintaudi A., Baldini M., Aringhieri S., et al. (2021). Atypical antipsychotics and metabolic syndrome: from molecular mechanisms to clinical differences. Pharmaceuticals (Basel) 14 (3), 238. 10.3390/ph14030238</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph14030238</ArticleId><ArticleId IdType="pmc">PMC8001502</ArticleId><ArticleId IdType="pubmed">33800403</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheeley M. K., Saseen J. J., Agarwala A., Ravilla S., Ciffone N., Jacobson T. A., et al. (2022). NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. J. Clin. Lipidol. 16 (4), 361&#x2013;375. 10.1016/j.jacl.2022.05.068</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacl.2022.05.068</ArticleId><ArticleId IdType="pubmed">35718660</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L., Liang Y. H., Pei S. C., Feng Y. P., Wei M. (2011a). Effects of flavonoids from persimmon leaves on the activities of hepatic lipoprotein metabolism-related enzymes and antioxidant capacity in rats with hyperlipidemia. Chin. J. Nat. Med. 9 (01), 74&#x2013;77.</Citation></Reference><Reference><Citation>Chen Y. Z., Wu M., Zhang X. B., Yan J. H. (2011b). Effects of flavonoids from persimmon leaves on atherosclerosis in apolipoprotein E-deficient mice. Chin. J. Gerontology 31 (12), 2233&#x2013;2234.</Citation></Reference><Reference><Citation>Chinese Society of Cardiology C.M.A.C.P.a.R.C. Chinese Association of Rehabilitation Medicine Cardiology Committee, Chinese Geriatrics and Gerontology Society Thrombosis Prevention and Treatment Committee, Cardiovascular Medicine Branch Chinese Medical Doctor Association (2023). Chinese guidelines for primary prevention of cardiovascular diseases (primary care version). Chin. J. Cardiol. 51 (4), 343&#x2013;363. 10.3760/cma.j.cn112148-20230106-00014</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.cn112148-20230106-00014</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinetti-Gbaguidi G., Baron M., Bouhlel M. A., Vanhoutte J., Copin C., Sebti Y., et al. (2011). Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPAR&#x3b3; and LXR&#x3b1; pathways. Circ. Res. 108 (8), 985&#x2013;995. 10.1161/circresaha.110.233775</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circresaha.110.233775</ArticleId><ArticleId IdType="pmc">PMC3319502</ArticleId><ArticleId IdType="pubmed">21350215</ArticleId></ArticleIdList></Reference><Reference><Citation>Corey K. E., Chalasani N. (2014). Management of dyslipidemia as a cardiovascular risk factor in individuals with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 12 (7), 1077&#x2013;1084. 10.1016/j.cgh.2013.08.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2013.08.014</ArticleId><ArticleId IdType="pmc">PMC3933450</ArticleId><ArticleId IdType="pubmed">23962548</ArticleId></ArticleIdList></Reference><Reference><Citation>DerSimonian R., Laird N. (1986). Meta-analysis in clinical trials. Control Clin. Trials 7 (3), 177&#x2013;188. 10.1016/0197-2456(86)90046-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-2456(86)90046-2</ArticleId><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Y. (2022). Clinical efficacy of naoxinging capsule combined with levosimendanin the treatment of chronic heart failure. Henan Med. Res. 31 (05), 896&#x2013;899.</Citation></Reference><Reference><Citation>Fareed N., El-Kersh D. M., Youssef F. S., Labib R. M. (2022). Unveiling major ethnopharmacological aspects of genus Diospyros in context to its chemical diversity: a comprehensive overview. J. Food Biochem. 46 (12), e14413. 10.1111/jfbc.14413</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jfbc.14413</ArticleId><ArticleId IdType="pubmed">36136087</ArticleId></ArticleIdList></Reference><Reference><Citation>F&#xf6;rstermann U., Xia N., Li H. (2017). Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis. Circ. Res. 120 (4), 713&#x2013;735. 10.1161/circresaha.116.309326</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circresaha.116.309326</ArticleId><ArticleId IdType="pubmed">28209797</ArticleId></ArticleIdList></Reference><Reference><Citation>Gai W. (2020). Primary prevention of cerebrovascular diseases. Chin. J. Neurology 53 (8), 614&#x2013;622. 10.3760/cma.j.cn113694-20200414-00265</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.cn113694-20200414-00265</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y., Liu J., Liu X., Hao Y., Pan Z., He X., et al. (2025). Persimmon leaf extract ameliorates hyperlipidemia by modulating lipid genes expression and gut microbiota in high-fat-diet-fed mice. J. Sci. Food Agric. 105 (9), 5074&#x2013;5089. 10.1002/jsfa.14248</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jsfa.14248</ArticleId><ArticleId IdType="pubmed">40165393</ArticleId></ArticleIdList></Reference><Reference><Citation>He C., T. Q., He J. X., Wen J., Yin R. L. (2017). Optimization of the prescription for oral disintegrating tablets of persimmon leaf total flavonoid solid dispersion. Tradit. Chin. Pat. Med. 39 (12), 2513&#x2013;2517.</Citation></Reference><Reference><Citation>Higgins J. P., Thompson S. G., Deeks J. J., Altman D. G. (2003). Measuring inconsistency in meta-analyses. BMJ 327 (7414), 557&#x2013;560. 10.1136/bmj.327.7414.557</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.327.7414.557</ArticleId><ArticleId IdType="pmc">PMC192859</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins J. P., Altman D. G., G&#xf8;tzsche P. C., J&#xfc;ni P., Moher D., Oxman A. D., et al. (2011). The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Bmj 343, d5928. 10.1136/bmj.d5928</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d5928</ArticleId><ArticleId IdType="pmc">PMC3196245</ArticleId><ArticleId IdType="pubmed">22008217</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong E. L., Liao X. J., Chang F. K. (2017). Effects of naoxinqing tablets on glucose and lipid metabolism in schizophrenia patients treated with olanzapine. J. Mod. Integr. Med. Traditional Chin. West. Med. 26 (15), 1686&#x2013;1687+1692.</Citation></Reference><Reference><Citation>Hong C., Wang X., Xu J., Guo J., Peng H., Zhang Y. (2023). A review: pharmacological effect of natural compounds in Diospyros kaki leaves from the perspective of oxidative stress. Molecules 29 (1), 215. 10.3390/molecules29010215</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules29010215</ArticleId><ArticleId IdType="pmc">PMC10780463</ArticleId><ArticleId IdType="pubmed">38202798</ArticleId></ArticleIdList></Reference><Reference><Citation>Hossain A., Shahidi F. (2023). Persimmon leaves: nutritional, pharmaceutical, and industrial potential-a review. Plants (Basel) 12 (4), 937. 10.3390/plants12040937</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/plants12040937</ArticleId><ArticleId IdType="pmc">PMC9965245</ArticleId><ArticleId IdType="pubmed">36840285</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu M. W. a.S. (2012). Effects of flavonoids from persimmon leaves on the function of vascular endothelial cells in rats with hyperlipidemia. Chin. J. Exp. Traditional Med. Formulae 18 (13), 242&#x2013;244. 10.13422/j.cnki.syfjx.2012.13.076</Citation><ArticleIdList><ArticleId IdType="doi">10.13422/j.cnki.syfjx.2012.13.076</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X. Z. (2013). Discussion on the treatment of essential hypertension with the combination of valsartan and naoxinqing tablets. J. Clin. Ration. Drug Use 6 (05), 36&#x2013;37. 10.15887/j.cnki.13-1389/r.2013.05.090</Citation><ArticleIdList><ArticleId IdType="doi">10.15887/j.cnki.13-1389/r.2013.05.090</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S. W., Zhang M. Y., Liu Q. B., Luo S. Y., Peng Y., Sun B., et al. (2016). The effect of ethyl acetate extract from persimmon leaves on Alzheimer&#x2019;s disease and its underlying mechanism. Phytomedicine 23 (7), 694&#x2013;704. 10.1016/j.phymed.2016.03.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phymed.2016.03.009</ArticleId><ArticleId IdType="pubmed">27235708</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y. F., Liu T. T., Fan W. J. (2024). Observation on the efficacy of naoxinqing capsules combined with metoprolol in the treatment of stable angina pectoris. Mod. Med. Clin. Appl. 39 (10), 2556&#x2013;2560.</Citation></Reference><Reference><Citation>Jung U. J., Park Y. B., Kim S. R., Choi M. S. (2012). Supplementation of persimmon leaf ameliorates hyperglycemia, dyslipidemia and hepatic fat accumulation in type 2 diabetic mice. PLoS One 7 (11), e49030. 10.1371/journal.pone.0049030</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0049030</ArticleId><ArticleId IdType="pmc">PMC3493507</ArticleId><ArticleId IdType="pubmed">23145054</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazzem M., Sun Y. T., Low M., Seto S. W., Chang D., Lee S., et al. (2019). Chromatographic analysis and anti-oxidative property of naoxinqing tablet, a proprietary preparation of Diospyros kaki leaves. Molecules 24 (6), 1101. 10.3390/molecules24061101</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules24061101</ArticleId><ArticleId IdType="pmc">PMC6470564</ArticleId><ArticleId IdType="pubmed">30897753</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim G. Y., Kim J. K., Kang W. W., Kim J. G., Joo G. J. (2005). Shelf-life extension of rice cake by the addition of persimmon leaf tea powder. Food Sci. Biotechnol. 14 (2), 196&#x2013;199.</Citation></Reference><Reference><Citation>Kim A. H., Kim H. J., Ryu R., Han H. J., Han Y. J., Lee M. K., et al. (2016). A mixture of ethanol extracts of persimmon leaf and citrus junos sieb improves blood coagulation parameters and ameliorates lipid metabolism disturbances caused by diet-induced obesity in C57BL/6J mice. J. Microbiol. Biotechnol. 26 (2), 295&#x2013;308. 10.4014/jmb.1509.09050</Citation><ArticleIdList><ArticleId IdType="doi">10.4014/jmb.1509.09050</ArticleId><ArticleId IdType="pubmed">26699754</ArticleId></ArticleIdList></Reference><Reference><Citation>Klempfner R., Erez A., Sagit B. Z., Goldenberg I., Fisman E., Kopel E., et al. (2016). Elevated triglyceride level is independently associated with increased all-cause mortality in patients with established coronary heart disease: twenty-two-year follow-up of the bezafibrate infarction prevention study and registry. Circ. Cardiovasc Qual. Outcomes 9 (2), 100&#x2013;108. 10.1161/circoutcomes.115.002104</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circoutcomes.115.002104</ArticleId><ArticleId IdType="pubmed">26957517</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamprecht D. G., Jr., Saseen J. J., Shaw P. B. (2022). Clinical conundrums involving statin drug-drug interactions. Prog. Cardiovasc Dis. 75, 83&#x2013;89. 10.1016/j.pcad.2022.11.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pcad.2022.11.002</ArticleId><ArticleId IdType="pubmed">36400235</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J. S., Lee M. K., Ha T. Y., Bok S. H., Park H. M., Jeong K. S., et al. (2006). Supplementation of whole persimmon leaf improves lipid profiles and suppresses body weight gain in rats fed high-fat diet. Food Chem. Toxicol. 44 (11), 1875&#x2013;1883. 10.1016/j.fct.2006.06.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fct.2006.06.014</ArticleId><ArticleId IdType="pubmed">16904806</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G., Zhu Y., Zhang Y., Lang J., Chen Y., Ling W. (2013). Estimated daily flavonoid and stilbene intake from fruits, vegetables, and nuts and associations with lipid profiles in Chinese adults. J. Acad. Nutr. Diet. 113 (6), 786&#x2013;794. 10.1016/j.jand.2013.01.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jand.2013.01.018</ArticleId><ArticleId IdType="pubmed">23522824</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Y. H., Wu G., Yang Z. J. (2013). Preparation of flavonoid sustained-release tablets from persimmon leaves and determination of their release rate. Chin. Propr. Med. 35 (10), 2134&#x2013;2137.</Citation></Reference><Reference><Citation>Liang Q., Cai Y., Chen R., Chen W., Chen L., Xiao Y. (2022). Effect of naoxinging tablet in the treatment of convalescent stroke: a multicenter, randomized, double-blind, control trial. Chin. Archives Traditional Chin. Med. 42 (07), 802&#x2013;810.</Citation></Reference><Reference><Citation>Liu F. R. (2019). Observation on the efficacy of naoxinqing in treating the elevated blood lipid levels in female schizophrenia patients caused by olanzapine. Prim. Med. Forum 23 (02), 165&#x2013;166. 10.19435/j.1672-1721.2019.02.008</Citation><ArticleIdList><ArticleId IdType="doi">10.19435/j.1672-1721.2019.02.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W. F. (2023). Improvement of the quality standards for naoxinqing tablets. Chin. Pat. Med. 45 (12), 3910&#x2013;3913.</Citation></Reference><Reference><Citation>Luo J., Xu T., Huang W. H., Li M. M. (2004). Research on the quality standards of naoxinqing tablets. Chin. J. New Drugs (07), 625&#x2013;627.</Citation></Reference><Reference><Citation>Lv X. W., Qu J. G., Dong W. T., Liu C. Y. (2020). Therapeutic effect of naoxinqing tablets combined with atorvastatin in patients with Acute cerebral infarction. J. Math. Med. 33 (08), 1188&#x2013;1189.</Citation></Reference><Reference><Citation>Mach F., Baigent C., Catapano A. L., Koskinas K. C., Casula M., Badimon L., et al. (2020). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J. 41 (1), 111&#x2013;188. 10.1093/eurheartj/ehz455</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehz455</ArticleId><ArticleId IdType="pubmed">31504418</ArticleId></ArticleIdList></Reference><Reference><Citation>Maitra U., Parks J. S., Li L. (2009). An innate immunity signaling process suppresses macrophage ABCA1 expression through IRAK-1-mediated downregulation of retinoic acid receptor alpha and NFATc2. Mol. Cell Biol. 29 (22), 5989&#x2013;5997. 10.1128/mcb.00541-09</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mcb.00541-09</ArticleId><ArticleId IdType="pmc">PMC2772564</ArticleId><ArticleId IdType="pubmed">19752193</ArticleId></ArticleIdList></Reference><Reference><Citation>Marston N. A., Giugliano R. P., Im K., Silverman M. G., O'Donoghue M. L., Wiviott S. D., et al. (2019). Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: a systematic review and meta-regression analysis of randomized controlled trials. Circulation 140 (16), 1308&#x2013;1317. 10.1161/circulationaha.119.041998</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circulationaha.119.041998</ArticleId><ArticleId IdType="pmc">PMC6791781</ArticleId><ArticleId IdType="pubmed">31530008</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman C. B. (2022). Safety of statins and nonstatins for treatment of dyslipidemia. Endocrinol. Metab. Clin. North Am. 51 (3), 655&#x2013;679. 10.1016/j.ecl.2022.01.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ecl.2022.01.004</ArticleId><ArticleId IdType="pubmed">35963634</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols G. A., Philip S., Reynolds K., Granowitz C. B., Fazio S. (2019). Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol. Diabetes Obes. Metab. 21 (2), 366&#x2013;371. 10.1111/dom.13537</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.13537</ArticleId><ArticleId IdType="pmc">PMC6587847</ArticleId><ArticleId IdType="pubmed">30225881</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan C. W., W. W., Xie Y. F., Qi X. Z., Jiang L. X. (2016). Effects of persimmon leaves on oxygen free radicals and lipid metabolism enzymes in rats with hyperlipidemia. Guid. J. Traditional Chin. Med. Pharm. 22 (20), 42&#x2013;44. 10.13862/j.cnki.cn43-1446/r.2016.20.015</Citation><ArticleIdList><ArticleId IdType="doi">10.13862/j.cnki.cn43-1446/r.2016.20.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirillo A., Casula M., Olmastroni E., Norata G. D., Catapano A. L. (2021). Global epidemiology of dyslipidaemias. Nat. Rev. Cardiol. 18 (10), 689&#x2013;700. 10.1038/s41569-021-00541-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-021-00541-4</ArticleId><ArticleId IdType="pubmed">33833450</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiao Z. L., Li X. F., Feng S. J., Yang J. X. (2013). Effects of naoxinqing tablets on patients with coronary atherosclerotic heart disease. New J. Traditional Chin. Med. 45 (09), 15&#x2013;16. 10.13457/j.cnki.jncm.2013.09.007</Citation><ArticleIdList><ArticleId IdType="doi">10.13457/j.cnki.jncm.2013.09.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Ram&#xed;rez-Briones E., Rodr&#xed;guez-Mac&#xed;as R., Salcedo-P&#xe9;rez E., Ram&#xed;rez-Ch&#xe1;vez E., Molina-Torres J., Tiessen A., et al. (2019). Seasonal changes in the metabolic profiles and biological activity in leaves of Diospyros digyna and D. Rekoi &#x201c;Zapote&#x201d; Trees. Plants (Basel) 8 (11), 449. 10.3390/plants8110449</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/plants8110449</ArticleId><ArticleId IdType="pmc">PMC6918230</ArticleId><ArticleId IdType="pubmed">31731430</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauf A., Uddin G., Patel S., Khan A., Halim S. A., Bawazeer S., et al. (2017). Diospyros, an under-utilized, multi-purpose plant genus: a review. Biomed. Pharmacother. 91, 714&#x2013;730. 10.1016/j.biopha.2017.05.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2017.05.012</ArticleId><ArticleId IdType="pubmed">28499243</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruscica M., Macchi C., Morlotti B., Sirtori C. R., Magni P. (2014). Statin therapy and related risk of new-onset type 2 diabetes mellitus. Eur. J. Intern Med. 25 (5), 401&#x2013;406. 10.1016/j.ejim.2014.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2014.03.003</ArticleId><ArticleId IdType="pubmed">24685426</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakanaka S., Tachibana Y., Okada Y. (2005). Preparation and antioxidant properties of extracts of Japanese persimmon leaf tea (kakinoha-cha). Food Chem. 89 (4), 569&#x2013;575. 10.1016/j.foodchem.2004.03.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.foodchem.2004.03.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Shea B. J., Reeves B. C., Wells G., Thuku M., Hamel C., Moran J., et al. (2017). AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. Bmj 358, j4008. 10.1136/bmj.j4008</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.j4008</ArticleId><ArticleId IdType="pmc">PMC5833365</ArticleId><ArticleId IdType="pubmed">28935701</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverman M. G., Ference B. A., Im K., Wiviott S. D., Giugliano R. P., Grundy S. M., et al. (2016). Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA 316 (12), 1289&#x2013;1297. 10.1001/jama.2016.13985</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.13985</ArticleId><ArticleId IdType="pubmed">27673306</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroes E. S., Thompson P. D., Corsini A., Vladutiu G. D., Raal F. J., Ray K. K., et al. (2015). Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management. Eur. Heart J. 36 (17), 1012&#x2013;1022. 10.1093/eurheartj/ehv043</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehv043</ArticleId><ArticleId IdType="pmc">PMC4416140</ArticleId><ArticleId IdType="pubmed">25694464</ArticleId></ArticleIdList></Reference><Reference><Citation>Su M. L. a.G. (1436). Southern Yunnan herbs. Kunming: Yunnan Science and Technology Press.</Citation></Reference><Reference><Citation>Tang B. S., Liang Z. W., Deng W. Q., Jiang Y. Z., Wu H. L., Chen B. (2012). 35 cases of naoxinqing tablets in adjuvant treatment of diabetic cerebral infarction. Glob. Tradit. Chin. Med. 5 (08), 616&#x2013;618.</Citation></Reference><Reference><Citation>Vaduganathan M., Mensah G. A., Turco J. V., Fuster V., Roth G. A. (2022). The Global Burden of cardiovascular diseases and risk: a compass for future health. J. Am. Coll. Cardiol. 80 (25), 2361&#x2013;2371. 10.1016/j.jacc.2022.11.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2022.11.005</ArticleId><ArticleId IdType="pubmed">36368511</ArticleId></ArticleIdList></Reference><Reference><Citation>Visseren F. L. J., Mach F., Smulders Y. M., Carballo D., Koskinas K. C., B&#xe4;ck M., et al. (2021). 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. 42 (34), 3227&#x2013;3337. 10.1093/eurheartj/ehab484</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab484</ArticleId><ArticleId IdType="pubmed">34458905</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C. Y. a.W. L. (2016). Observation on the efficacy of naoxinqing combined with fluvastatin in the treatment of elderly lower extremity arteriosclerosis obliterans. Guide Chin. Med. 14 (28), 189&#x2013;190. 10.15912/j.cnki.gocm.2016.28.156</Citation><ArticleIdList><ArticleId IdType="doi">10.15912/j.cnki.gocm.2016.28.156</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y. C. a. X. (2023). Expert consensus on the clinical application of naoxinqing tablets in treating ischemic cerebrovascular diseases. Chin. Archives Traditional Chin. Med. 41 (05), 247&#x2013;253. 10.13193/j.issn.1673-7717.2023.05.052</Citation><ArticleIdList><ArticleId IdType="doi">10.13193/j.issn.1673-7717.2023.05.052</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., O. Y., Liu J., Zhao G. (2014). Flavonoid intake and risk of CVD: a systematic review and meta-analysis of prospective cohort studies. Br. J. Nutr. 111 (1), 1&#x2013;11. 10.1017/s000711451300278x</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/s000711451300278x</ArticleId><ArticleId IdType="pubmed">23953879</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J. X. L., Tian Y., Li X. J., Wang L. Y., Wang L., Yang B. H., et al. (2023a). Flavonoids from persimmon leaves improve hepatic steatosis in rats with non-alcoholic fatty liver disease (NAFLD) by activating autophagy and synergistically acting on antioxidant stress. Tianjin Med. J. 51 (11), 1211&#x2013;1216.</Citation></Reference><Reference><Citation>Wang J. L., Li J. J., Wu G. P., Chen Z. Y., Zhao D., Zhao S. P., et al. (2023b). Chinese lipid management guidelines (2023). Chin. Circ. J. 38 (03), 237&#x2013;271.</Citation></Reference><Reference><Citation>Wei C., Cheng W. H., Han C. L. (2018). Research on the influence of persimmon leaf extract on blood lipid levels in elderly patients with primary hyperlipidemia. J. Math. Med. 31 (8), 1206&#x2013;1207. 10.3969/j.issn.1004-4337.2018.08.046</Citation><ArticleIdList><ArticleId IdType="doi">10.3969/j.issn.1004-4337.2018.08.046</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong N. D., Budoff M. J., Ferdinand K., Graham I. M., Michos E. D., Reddy T., et al. (2022). Atherosclerotic cardiovascular disease risk assessment: an American Society for Preventive Cardiology clinical practice statement. Am. J. Prev. Cardiol. 10, 100335. 10.1016/j.ajpc.2022.100335</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpc.2022.100335</ArticleId><ArticleId IdType="pmc">PMC8943256</ArticleId><ArticleId IdType="pubmed">35342890</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J. L. (2004). Clinical evaluation of naoxinqing tablets in the treatment of coronary heart disease with angina pectoris. Guangdong Pharm. J. (06), 41&#x2013;43.</Citation></Reference><Reference><Citation>Wu X. L., Wang M. J., Qi Y., Zhang W. J., Ao Q. X. (2008). Clinical study on the effects of naoxinqing tablets on blood lipids and blood viscosity. Chin. Herb. Med. (01), 171&#x2013;174. 10.13863/j.issn1001-4454.2008.01.061</Citation><ArticleIdList><ArticleId IdType="doi">10.13863/j.issn1001-4454.2008.01.061</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie C., Xie Z., Xu X., Yang D. (2015). Persimmon (Diospyros kaki L.) leaves: a review on traditional uses, phytochemistry and pharmacological properties. J. Ethnopharmacol. 163, 229&#x2013;240. 10.1016/j.jep.2015.01.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2015.01.007</ArticleId><ArticleId IdType="pubmed">25637828</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong Y. Q., Tan X. L., Zou J. K. (2013). Clinical analysis of integrated traditional Chinese and Western medicine therapy for unstable angina pectoris in elderly patients. Chin. Foreign Med. Res. (12), 36&#x2013;37.</Citation></Reference><Reference><Citation>Yang Z. Y., Ma C. H., Yuan M. Y., Yang Y., Wang Y. J., Liu L. H. (2014). Effects of persimmon leaf flavonoid preparations and simvastatin on serum inflammatory factors and lipoprotein(a) levels in hypertensive patients. Chin. J. Arteriosclerosis 22 (10), 1044&#x2013;1048.</Citation></Reference><Reference><Citation>Zhang S. T. a.L. C. (2021). Clinical study on naoxinqing capsules in delaying the progression of cerebral arteriosclerosis. World Latest Med. Inf. Abstr. 21 (34), 44&#x2013;46. 10.3969/j.issn.1671-3141.2021.34.016</Citation><ArticleIdList><ArticleId IdType="doi">10.3969/j.issn.1671-3141.2021.34.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q. Y., Zhao Y. Y., Wang L., Wang H. L. (2005). The effects of persimmon leaf extracts on blood glucose and lipid levels in streptozotocin-induced diabetic mice. J. Third Mil. Med. Univ. 14, 1449&#x2013;1452.</Citation></Reference><Reference><Citation>Zhao L. D. a. H. C. (2015). Research on the preparation technology of ointment containing total flavonoids from persimmon leaves. Heilongjiang Animal Sci. Veterinary Med., 173&#x2013;175. 10.13881/j.cnki.hljxmsy.2015.0538</Citation><ArticleIdList><ArticleId IdType="doi">10.13881/j.cnki.hljxmsy.2015.0538</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao R. F. (2016). Observation on the efficacy of naoxinqing tablets combined with cinnarizine in treating dizziness in patients with chronic cerebral hypoperfusion. Lingnan J. Emerg. Med. 21 (04), 381&#x2013;382.</Citation></Reference><Reference><Citation>Zhou X. W. a. H. (2023). Study on the effect of persimmon leaf total flavonoids in inhibiting lipid accumulation in macrophage-derived foam cells. J. Hubei Univ. Sci. Technol. 37 (05), 374&#x2013;378. 10.16751/j.cnki.2095-4646.2023.05.0374</Citation><ArticleIdList><ArticleId IdType="doi">10.16751/j.cnki.2095-4646.2023.05.0374</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X. C., Pan C. Q., Gao M. (2015). Observation on the efficacy of persimmon leaf extract in the secondary prevention of ischemic cerebrovascular diseases. Chin. J. Biochem. Pharmaceuticals Clin. 35 (04), 112&#x2013;115.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">41024970</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1949-8462</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>26</Day></PubDate></JournalIssue><Title>World journal of cardiology</Title><ISOAbbreviation>World J Cardiol</ISOAbbreviation></Journal><ArticleTitle>Coronary computed tomography angiography <i>vs</i> stress testing for stable angina evaluation: Diagnostic and prognostic superiority.</ArticleTitle><Pagination><StartPage>110061</StartPage><MedlinePgn>110061</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">110061</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.4330/wjc.v17.i9.110061</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Stable angina pectoris, a clinical manifestation of coronary artery disease (CAD), is commonly evaluated using non-invasive diagnostic tools. Traditionally, stress testing modalities such as exercise electrocardiography (ECG), myocardial perfusion imaging (MPI), and stress echocardiography have been the first-line strategies. However, coronary computed tomography angiography (CCTA), an anatomic imaging modality, is increasingly used for its ability to directly visualize coronary artery stenoses and plaque burden. Despite growing adoption, the comparative effectiveness of CCTA and stress testing in terms of diagnostic accuracy, prognostic value, and clinical outcomes in stable angina remains an area of active debate.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To compare the diagnostic and prognostic performance of CCTA with various forms of stress testing in adult patients presenting with suspected or confirmed stable angina.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A comprehensive literature search was performed across PubMed, EMBASE, Scopus, and the Cochrane Central Register of Controlled Trials in accordance with the PRISMA guidelines. Only randomized controlled trials (RCT) published in English within the last 15 years were included. Studies involving adult patients (&#x2265; 18 years) with stable angina or low-risk chest pain were selected. The intervention was CCTA, and the comparators included ECG, MPI, and stress echocardiography. Data were extracted using a standardized process, and study quality was assessed using the Cochrane Risk of Bias 2.0 tool. Due to heterogeneity in outcome measures and modalities, narrative synthesis was employed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Five high-quality RCTs encompassing a total of 5551 patients were included. CCTA demonstrated superior diagnostic accuracy and prognostic capability across multiple studies. It was more effective in predicting major adverse cardiac events, including myocardial infarction and cardiac death, and was associated with fewer unnecessary invasive coronary angiographies and better event-free survival. Studies also reported improved revascularization rates in patients evaluated with CCTA, particularly within tiered diagnostic protocols. Stress testing, while useful, showed limitations in sensitivity and downstream clinical decision-making.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">CCTA offers a diagnostically superior and clinically impactful strategy for the initial evaluation of patients with stable angina, especially those with intermediate pretest probability of CAD. Compared to conventional stress testing, it enhances risk stratification, reduces unnecessary procedures, and may improve long-term outcomes. These findings support its broader integration into diagnostic pathways for stable angina.</AbstractText><CopyrightInformation>&#xa9;The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gundareddy</LastName><ForeName>Vinay</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Internal Medicine, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singla</LastName><ForeName>Shivam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Internal Medicine, Tidal Health Peninsula Regional, Salisbury, NC 21801, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mounika</LastName><ForeName>Jupalle</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Internal Medicine, Kurnool Medical College, Kurnool 518002, Andhra Pradesh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Owona</LastName><ForeName>Okello</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Internal Medicine, Ministry of Health, Lusaka 10101, Zambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singla</LastName><ForeName>Bhavna</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Internal Medicine, Erie County Medical Center, Buffalo, NY 14215, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Taranpreet</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Internal Medicine, Mahatma Gandhi Mission Medical College and Hospital, Navi Mumbai 410209, Maharashtra, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anwar</LastName><ForeName>Sidra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Internal Medicine, Shaikh Zayed Hospital, Lahore 54600, Punjab, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramachandran</LastName><ForeName>Vignesh</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Internal Medicine, Melmaruvathur Adhiparasakthi Institute of Medical Sciences and Research, Melmaruvathur 603319, Tamil N&#x101;du, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ullah</LastName><ForeName>Hikmat</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Internal Medicine, Allama Iqbal Medical College, Lahore 54550, Punjab, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazari</LastName><ForeName>Shabbir</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Internal Medicine, Kabul Medical University, Kabul 100306, Afghanistan. shabbirmazari826@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>World J Cardiol</MedlineTA><NlmUniqueID>101537090</NlmUniqueID></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coronary artery disease</Keyword><Keyword MajorTopicYN="N">Coronary computed tomography angiography</Keyword><Keyword MajorTopicYN="N">Diagnostic accuracy</Keyword><Keyword MajorTopicYN="N">Event-free survival</Keyword><Keyword MajorTopicYN="N">Myocardial perfusion imaging</Keyword><Keyword MajorTopicYN="N">Non-invasive cardiac imaging</Keyword><Keyword MajorTopicYN="N">Prognostic evaluation</Keyword><Keyword MajorTopicYN="N">Revascularization</Keyword><Keyword MajorTopicYN="N">Stable angina</Keyword><Keyword MajorTopicYN="N">Stress testing</Keyword></KeywordList><CoiStatement>Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>30</Day><Hour>4</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41024970</ArticleId><ArticleId IdType="pmc">PMC12476583</ArticleId><ArticleId IdType="doi">10.4330/wjc.v17.i9.110061</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gillen C, Goyal A. Stable Angina. 2022 Dec 19. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-</Citation><ArticleIdList><ArticleId IdType="pubmed">32644442</ArticleId></ArticleIdList></Reference><Reference><Citation>Senior R, Monaghan M, Becher H, Mayet J, Nihoyannopoulos P British Society of Echocardiography. Stress echocardiography for the diagnosis and risk stratification of patients with suspected or known coronary artery disease: a critical appraisal. Supported by the British Society of Echocardiography. Heart. 2005;91:427&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1768798</ArticleId><ArticleId IdType="pubmed">15772187</ArticleId></ArticleIdList></Reference><Reference><Citation>Ananthasubramaniam G, Ananthasubramaniam K. Stress electrocardiography testing in coronary artery disease: Is it time for its swan song or to redefine its role in the modern era? Indian Heart J. 2022;74:81&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9039687</ArticleId><ArticleId IdType="pubmed">35167825</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh R, Patel A, Lu B, Senapati A, Mahmarian J, Chang SM. Cardiac Computed Tomography for Comprehensive Coronary Assessment: Beyond Diagnosis of Anatomic Stenosis. Methodist Debakey Cardiovasc J. 2020;16:77&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7350823</ArticleId><ArticleId IdType="pubmed">32670467</ArticleId></ArticleIdList></Reference><Reference><Citation>Budoff MJ, Lakshmanan S, Toth PP, Hecht HS, Shaw LJ, Maron DJ, Michos ED, Williams KA, Nasir K, Choi AD, Chinnaiyan K, Min J, Blaha M. Cardiac CT angiography in current practice: An American society for preventive cardiology clinical practice statement(&#x2730;) Am J Prev Cardiol. 2022;9:100318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8802838</ArticleId><ArticleId IdType="pubmed">35146468</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahsepar AA, Arbab-Zadeh A. Cardiac CT vs. Stress Testing in Patients with Suspected Coronary Artery Disease: Review and Expert Recommendations. Curr Cardiovasc Imaging Rep. 2015;8:29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4613789</ArticleId><ArticleId IdType="pubmed">26500716</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbosa MF, Canan A, Xi Y, Litt H, Diercks DB, Abbara S, Kay FU. Comparative Effectiveness of Coronary CT Angiography and Standard of Care for Evaluating Acute Chest Pain: A Living Systematic Review and Meta-Analysis. Radiol Cardiothorac Imaging. 2023;5:e230022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10483255</ArticleId><ArticleId IdType="pubmed">37693194</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown D. A Review of the PubMed PICO Tool: Using Evidence-Based Practice in Health Education. Health Promot Pract. 2020;21:496&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pubmed">31874567</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2707599</ArticleId><ArticleId IdType="pubmed">19621072</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Bias.  RoB 2: A revised Cochrane risk-of-bias tool for randomized trials. [cited 2 April 2025]. Available from: https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-randomized-trials .</Citation></Reference><Reference><Citation>Singh T, Bing R, Dweck MR, van Beek EJR, Mills NL, Williams MC, Villines TC, Newby DE, Adamson PD. Exercise Electrocardiography and Computed Tomography Coronary Angiography for Patients With Suspected Stable Angina Pectoris: A Post Hoc Analysis of the Randomized SCOT-HEART Trial. JAMA Cardiol. 2020;5:920&#x2013;928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7271417</ArticleId><ArticleId IdType="pubmed">32492104</ArticleId></ArticleIdList></Reference><Reference><Citation>Stillman AE, Gatsonis C, Lima JAC, Liu T, Snyder BS, Cormack J, Malholtra V, Schnall MD, Udelson JE, Hoffmann U, Woodard PK RESCUE investigators *. Coronary Computed Tomography Angiography Compared With Single Photon Emission Computed Tomography Myocardial Perfusion Imaging as a Guide to Optimal Medical Therapy in Patients Presenting With Stable Angina: The RESCUE Trial. J Am Heart Assoc. 2020;9:e017993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7955393</ArticleId><ArticleId IdType="pubmed">33283579</ArticleId></ArticleIdList></Reference><Reference><Citation>Lubbers M, Dedic A, Coenen A, Galema T, Akkerhuis J, Bruning T, Krenning B, Musters P, Ouhlous M, Liem A, Niezen A, Hunink M, de Feijter P, Nieman K. Calcium imaging and selective computed tomography angiography in comparison to functional testing for suspected coronary artery disease: the multicentre, randomized CRESCENT trial. Eur Heart J. 2016;37:1232&#x2013;1243.</Citation><ArticleIdList><ArticleId IdType="pubmed">26746631</ArticleId></ArticleIdList></Reference><Reference><Citation>Lubbers M, Coenen A, Kofflard M, Bruning T, Kietselaer B, Galema T, Kock M, Niezen A, Das M, van Gent M, van den Bos EJ, van Woerkens L, Musters P, Kooij S, Nous F, Budde R, Hunink M, Nieman K. Comprehensive Cardiac CT With Myocardial Perfusion Imaging Versus Functional Testing in Suspected Coronary Artery Disease: The Multicenter, Randomized CRESCENT-II Trial. JACC Cardiovasc Imaging. 2018;11:1625&#x2013;1636.</Citation><ArticleIdList><ArticleId IdType="pubmed">29248657</ArticleId></ArticleIdList></Reference><Reference><Citation>Linde JJ, Hove JD, S&#xf8;rgaard M, Kelb&#xe6;k H, Jensen GB, K&#xfc;hl JT, Hinds&#xf8; L, K&#xf8;ber L, Nielsen WB, Kofoed KF. Long-Term Clinical Impact of Coronary CT Angiography in Patients With Recent Acute-Onset Chest Pain: The Randomized Controlled CATCH Trial. JACC Cardiovasc Imaging. 2015;8:1404&#x2013;1413.</Citation><ArticleIdList><ArticleId IdType="pubmed">26577263</ArticleId></ArticleIdList></Reference><Reference><Citation>Mark DB, Anstrom KJ, Sheng S, Baloch KN, Daniels MR, Hoffmann U, Patel MR, Cooper LS, Lee KL, Douglas PS PROMISE Investigators. Quality-of-Life Outcomes With Anatomic Versus Functional Diagnostic Testing Strategies in Symptomatic Patients With Suspected Coronary Artery Disease: Results From the PROMISE Randomized Trial. Circulation. 2016;133:1995&#x2013;2007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4879021</ArticleId><ArticleId IdType="pubmed">27143676</ArticleId></ArticleIdList></Reference><Reference><Citation>Woods E, Bennett J, Chandrasekhar S, Newman N, Rizwan A, Siddiqui R, Khan R, Khawaja M, Krittanawong C. Efficacy of Diagnostic Testing of Suspected Coronary Artery Disease: A Contemporary Review. Cardiology. 2025;150:111&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11965859</ArticleId><ArticleId IdType="pubmed">39013364</ArticleId></ArticleIdList></Reference><Reference><Citation>Trost J, Ferraro RA, Sharma G, Hays AG, Boden WE, Blumenthal RS, Arbab-Zadeh A. CCTA Should Be the New Diagnostic Gateway for Evaluating Intermediate-Risk Stable Angina Patients. JACC Adv. 2022;1:100116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11198657</ArticleId><ArticleId IdType="pubmed">38939715</ArticleId></ArticleIdList></Reference><Reference><Citation>Marwick TH, Cho I, &#xd3; Hartaigh B, Min JK. Finding the Gatekeeper to the Cardiac Catheterization Laboratory: Coronary CT Angiography or Stress Testing? J Am Coll Cardiol. 2015;65:2747&#x2013;2756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4618380</ArticleId><ArticleId IdType="pubmed">26112200</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rosendael SE, Shiyovich A, Cardoso RN, Souza Freire CV, van Rosendael AR, Lin FY, Larocca G, Bienstock SW, Blankstein R, Shaw LJ. The Role of Cardiac Computed Tomography Angiography in Risk Stratification for Coronary Artery Disease. J Soc Cardiovasc Angiogr Interv. 2024;3:102230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11624369</ArticleId><ArticleId IdType="pubmed">39649823</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JAC, Savovi&#x107; J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hern&#xe1;n MA, Hopewell S, Hr&#xf3;bjartsson A, Junqueira DR, J&#xfc;ni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.</Citation><ArticleIdList><ArticleId IdType="pubmed">31462531</ArticleId></ArticleIdList></Reference><Reference><Citation>Danad I, Raijmakers PG, Driessen RS, Leipsic J, Raju R, Naoum C, Knuuti J, M&#xe4;ki M, Underwood RS, Min JK, Elmore K, Stuijfzand WJ, van Royen N, Tulevski II, Somsen AG, Huisman MC, van Lingen AA, Heymans MW, van de Ven PM, van Kuijk C, Lammertsma AA, van Rossum AC, Knaapen P. Comparison of Coronary CT Angiography, SPECT, PET, and Hybrid Imaging for Diagnosis of Ischemic Heart Disease Determined by Fractional Flow Reserve. JAMA Cardiol. 2017;2:1100&#x2013;1107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5710451</ArticleId><ArticleId IdType="pubmed">28813561</ArticleId></ArticleIdList></Reference><Reference><Citation>Thribhuvan Reddy D, Grewal I, Garc&#xed;a Pinzon LF, Latchireddy B, Goraya S, Ali Alansari B, Gadwal A. The Role of Artificial Intelligence in Healthcare: Enhancing Coronary Computed Tomography Angiography for Coronary Artery Disease Management. Cureus. 2024;16:e61523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11218716</ArticleId><ArticleId IdType="pubmed">38957241</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">41024968</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1949-8462</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>26</Day></PubDate></JournalIssue><Title>World journal of cardiology</Title><ISOAbbreviation>World J Cardiol</ISOAbbreviation></Journal><ArticleTitle>Fractional flow reserve guided percutaneous coronary intervention <i>vs</i> coronary artery bypass grafting for multivessel coronary artery disease: A meta-analysis.</ArticleTitle><Pagination><StartPage>111044</StartPage><MedlinePgn>111044</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">111044</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.4330/wjc.v17.i9.111044</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) are well-established treatments for multivessel coronary artery disease (CAD), a condition where multiple heart arteries are narrowed. A newer approach, fractional flow reserve (FFR)-guided PCI, uses a specialized measurement to select which artery blockages to treat, aiming to enhance patient outcomes. Despite its adoption, the comparative effectiveness of FFR-guided PCI <i>vs</i> CABG remains unclear, particularly regarding key health outcomes such as survival, heart-related complications, and the need for further procedures.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To evaluate the safety and effectiveness of FFR -guided PCI compared to CABG in patients with multivessel CAD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This meta-analysis followed standard reporting guidelines and included randomized controlled trials (RCTs) comparing FFR-guided PCI with CABG in patients with multivessel CAD. We searched medical databases, including PubMed, EMBASE, ScienceDirect, and ClinicalTrials.gov, from their start to May 2025. We calculated combined risk ratios (RRs) with 95% confidence intervals (95%CIs) to analyze the data.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Three RCTs were analyzed. There was no notable difference in all-cause mortality between FFR-guided PCI and CABG (RR = 1.01, 95%CI: 0.78-1.31, <i>P</i> = 0.93). However, FFR-guided PCI showed higher rates of major adverse cardiac events (MACEs; RR = 1.30, 95%CI: 1.11-1.52, <i>P</i> = 0.001), myocardial infarction (RR = 1.49, 95%CI: 1.11-2.01, <i>P</i> = 0.009), and repeat revascularization (RR = 2.25, 95%CI: 1.78-2.85, <i>P</i> &lt; 0.00001). Stroke rates were comparable between the two treatments (RR = 0.80, 95%CI: 0.54-1.20, <i>P</i> = 0.28).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">FFR-guided PCI and CABG have similar rates of all-cause mortality and stroke in patients with multivessel CAD. However, CABG results in fewer MACEs, myocardial infarctions, and repeat procedures.</AbstractText><CopyrightInformation>&#xa9;The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kataveni</LastName><ForeName>Suhas</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Gandhi Medical College, Hyderabad 500001, Telangana, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ellahi</LastName><ForeName>Ezza</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Aziz Fatimah Hospital, Faisalabad 37000, Punjab, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zafar</LastName><ForeName>Fabeha</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Dow University of Health Sciences, Karachi 75280, Sindh, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veettil</LastName><ForeName>Ihsan Noushad Karuppan</ForeName><Initials>INK</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Sree Narayana Medical College, Ernakulam 683594, Kerala, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iqbal</LastName><ForeName>Amna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Wah Medical College, Islamabad 47010, Islamabad, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhir</LastName><ForeName>Bhavya</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Government Medical College, Patiala 147001, Punjab, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabarish</LastName><ForeName>Shivani</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Gandhi Medical College, Hyderabad 500001, Telangana, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erambalur</LastName><ForeName>Sai</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Richmond Gabriel University, St. Vincent and Grenadines VCO130, Saint Vincent and the Grenadines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yathindra</LastName><ForeName>Meenakshi Reddy</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Kasturba Medical College, Mangalore 575001, Karnataka, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kvn</LastName><ForeName>Moukthika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Sri Venkateshwara Institute of Medical Sciences, Tirupati 517501, Andhra Pradesh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nawaz</LastName><ForeName>Shayan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University College of Medicine &amp; Dentistry, Lahore 54000, Punjab, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dudekula</LastName><ForeName>Satish Kumar</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University of Perpetual Help System Dalta, Las Pi&#xf1;as CPO 1740, Metro Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haq</LastName><ForeName>Usman Ul</ForeName><Initials>UU</Initials><AffiliationInfo><Affiliation>Department of Medicine, Medway Maritime Hospital NHS Foundation Trust, Gillingham ME7 5NY, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hussain</LastName><ForeName>Asraf</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Chitwan Medical College, Bharatpur 33915, Nepal. drasrafcardiology@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khawar</LastName><ForeName>Muhammad Muneeb</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Cardiology, King Edward Medical University, Lahore 05450, Punjab, Pakistan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>World J Cardiol</MedlineTA><NlmUniqueID>101537090</NlmUniqueID></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coronary artery bypass grafting</Keyword><Keyword MajorTopicYN="N">Fractional flow reserve</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Multivessel coronary artery disease</Keyword><Keyword MajorTopicYN="N">Percutaneous coronary intervention</Keyword></KeywordList><CoiStatement>Conflict-of-interest statement: The authors disclose that they have no conflict of interest related to the subject of this study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>30</Day><Hour>4</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41024968</ArticleId><ArticleId IdType="pmc">PMC12476596</ArticleId><ArticleId IdType="doi">10.4330/wjc.v17.i9.111044</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gul F, Parekh A. Multivessel Disease. 2023 Feb 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2025.</Citation><ArticleIdList><ArticleId IdType="pubmed">32491818</ArticleId></ArticleIdList></Reference><Reference><Citation>Van den Eynde J, Bomhals K, No&#xe9; D, Jacquemyn X, McCutcheon K, Bennett J, Puskas JD, Oosterlinck W. Revascularization strategies in patients with multivessel coronary artery disease: a Bayesian network meta-analysis. Interact Cardiovasc Thorac Surg. 2022;34:947&#x2013;957.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9159431</ArticleId><ArticleId IdType="pubmed">34964468</ArticleId></ArticleIdList></Reference><Reference><Citation>Sipahi I, Akay MH, Dagdelen S, Blitz A, Alhan C. Coronary artery bypass grafting vs percutaneous coronary intervention and long-term mortality and morbidity in multivessel disease: meta-analysis of randomized clinical trials of the arterial grafting and stenting era. JAMA Intern Med. 2014;174:223&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">24296767</ArticleId></ArticleIdList></Reference><Reference><Citation>Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, St&#xe5;hle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360:961&#x2013;972.</Citation><ArticleIdList><ArticleId IdType="pubmed">19228612</ArticleId></ArticleIdList></Reference><Reference><Citation>Pijls NH, De Bruyne B, Peels K, Van Der Voort PH, Bonnier HJ, Bartunek J Koolen JJ, Koolen JJ. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. N Engl J Med. 1996;334:1703&#x2013;1708.</Citation><ArticleIdList><ArticleId IdType="pubmed">8637515</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van' t Veer M, Klauss V, Manoharan G, Engstr&#xf8;m T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009;360:213&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">19144937</ArticleId></ArticleIdList></Reference><Reference><Citation>De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, Jagic N, M&#xf6;bius-Winkler S, Rioufol G, Witt N, Kala P, MacCarthy P, Engstr&#xf6;m T, Oldroyd KG, Mavromatis K, Manoharan G, Verlee P, Frobert O, Curzen N, Johnson JB, J&#xfc;ni P, Fearon WF FAME 2 Trial Investigators. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367:991&#x2013;1001.</Citation><ArticleIdList><ArticleId IdType="pubmed">22924638</ArticleId></ArticleIdList></Reference><Reference><Citation>Fearon WF, Zimmermann FM, Ding VY, Takahashi K, Piroth Z, van Straten AHM, Szekely L, Davidavi&#x10d;ius G, Kalinauskas G, Mansour S, Kharbanda R, &#xd6;stlund-Papadogeorgos N, Aminian A, Oldroyd KG, Al-Attar N, Jagic N, Dambrink JE, Kala P, Anger&#xe5;s O, MacCarthy P, Wendler O, Casselman F, Witt N, Mavromatis K, Miner SES, Sarma J, Engstr&#xf8;m T, Christiansen EH, Tonino PAL, Reardon MJ, Otsuki H, Kobayashi Y, Hlatky MA, Mahaffey KW, Desai M, Woo YJ, Yeung AC, Pijls NHJ, De Bruyne B. Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial. Lancet. 2025;405:1481&#x2013;1490.</Citation><ArticleIdList><ArticleId IdType="pubmed">40174598</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohr FW, Morice MC, Kappetein AP, Feldman TE, St&#xe5;hle E, Colombo A, Mack MJ, Holmes DR Jr, Morel MA, Van Dyck N, Houle VM, Dawkins KD, Serruys PW. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 2013;381:629&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pubmed">23439102</ArticleId></ArticleIdList></Reference><Reference><Citation>Head SJ, Davierwala PM, Serruys PW, Redwood SR, Colombo A, Mack MJ, Morice MC, Holmes DR Jr, Feldman TE, St&#xe5;hle E, Underwood P, Dawkins KD, Kappetein AP, Mohr FW. Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial. Eur Heart J. 2014;35:2821&#x2013;2830.</Citation><ArticleIdList><ArticleId IdType="pubmed">24849105</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Otsuki H, Zimmermann FM, Ding VY, Engstr&#xf8;m T, H&#xf8;rsted Thyregod HG, Beleslin B, Putnik S, Tapp L, Barker T, Redwood S, Young C, Bech GJ, Hoohenkerk GJF, De Bruyne B, Pijls NHJ, Fearon WF FAME 3 Trial Investigators. FFR-Guided Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting in Patients With Diabetes. JAMA Cardiol. 2025;10:603&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11904802</ArticleId><ArticleId IdType="pubmed">40072460</ArticleId></ArticleIdList></Reference><Reference><Citation>Fearon WF, Zimmermann FM, De Bruyne B, Piroth Z, van Straten AHM, Szekely L, Davidavi&#x10d;ius G, Kalinauskas G, Mansour S, Kharbanda R, &#xd6;stlund-Papadogeorgos N, Aminian A, Oldroyd KG, Al-Attar N, Jagic N, Dambrink JE, Kala P, Anger&#xe5;s O, MacCarthy P, Wendler O, Casselman F, Witt N, Mavromatis K, Miner SES, Sarma J, Engstr&#xf8;m T, Christiansen EH, Tonino PAL, Reardon MJ, Lu D, Ding VY, Kobayashi Y, Hlatky MA, Mahaffey KW, Desai M, Woo YJ, Yeung AC, Pijls NHJ FAME 3 Investigators. Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery. N Engl J Med. 2022;386:128&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">34735046</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Gioia G, Soto Flores N, Franco D, Colaiori I, Sonck J, Gigante C, Kodeboina M, Bartunek J, Vanderheyden M, Van Praet F, Casselman F, Degriek I, Stockman B, Barbato E, Collet C, De Bruyne B. Coronary Artery Bypass Grafting or Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Diabetic Patients With Multivessel Disease. Circ Cardiovasc Interv. 2020;13:e009157.</Citation><ArticleIdList><ArticleId IdType="pubmed">33040579</ArticleId></ArticleIdList></Reference><Reference><Citation>Dillen DMM, Otsuki H, Takahashi K, Kobayashi Y, Piroth Z, Noiseux N, Nakadi BE, Kalinauskas G, Szekely L, Davidavi&#x10d;ius G, Teeuwen K, Tonino PAL, Pijls NHJ, De Bruyne B, Fearon WF, Zimmermann FM. Impact of Bifurcation Lesions on Outcomes After FFR-Guided PCI or CABG. Circ Cardiovasc Interv. 2025;18:e014610.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11748902</ArticleId><ArticleId IdType="pubmed">39727036</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pubmed">20171303</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr&#xf3;bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Methods Bias.  RoB 2: A revised Cochrane risk-of-bias tool for randomized trials. [cited 10 June 2025]. Available from: https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-randomized-trials .</Citation></Reference><Reference><Citation>Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ, Rosenberg Y, Solomon SD, Desai AS, Gersh BJ, Magnuson EA, Lansky A, Boineau R, Weinberger J, Ramanathan K, Sousa JE, Rankin J, Bhargava B, Buse J, Hueb W, Smith CR, Muratov V, Bansilal S, King S 3rd, Bertrand M, Fuster V FREEDOM Trial Investigators. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012;367:2375&#x2013;2384.</Citation><ArticleIdList><ArticleId IdType="pubmed">23121323</ArticleId></ArticleIdList></Reference><Reference><Citation>Serruys PW, Kogame N, Katagiri Y, Modolo R, Buszman PE, &#xcd;&#xf1;iguez-Romo A, Goicolea J, Hildick-Smith D, Ochala A, Dudek D, Piek JJ, Wykrzykowska JJ, Escaned J, Banning AP, Farooq V, Onuma Y. Clinical outcomes of state-of-the-art percutaneous coronary revascularisation in patients with three-vessel disease: two-year follow-up of the SYNTAX II study. EuroIntervention. 2019;15:e244&#x2013;e252.</Citation><ArticleIdList><ArticleId IdType="pubmed">30636684</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaudino MFL, An KR, Calhoon J. Mechanisms for the Superiority of Coronary Artery Bypass Grafting in Complex Coronary Artery Disease. Ann Thorac Surg. 2023;115:1333&#x2013;1336.</Citation><ArticleIdList><ArticleId IdType="pubmed">36587780</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren J, Siderakis C, Royse C, Hwang B, Royse A. Is total arterial coronary artery bypass grafting the next step forward? Vessel Plus. 2024;8:40.</Citation></Reference><Reference><Citation>Koo BK, Hu X, Kang J, Zhang J, Jiang J, Hahn JY, Nam CW, Doh JH, Lee BK, Kim W, Huang J, Jiang F, Zhou H, Chen P, Tang L, Jiang W, Chen X, He W, Ahn SG, Yoon MH, Kim U, Lee JM, Hwang D, Ki YJ, Shin ES, Kim HS, Tahk SJ, Wang J FLAVOUR Investigators. Fractional Flow Reserve or Intravascular Ultrasonography to Guide PCI. N Engl J Med. 2022;387:779&#x2013;789.</Citation><ArticleIdList><ArticleId IdType="pubmed">36053504</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakata K, Nakahashi T, Kawashiri MA. Prognostic superiority of coronary artery bypass grafting to percutaneous coronary intervention in non-diabetic patients with anatomically complex multivessel coronary artery disease. Cardiovasc Diagn Ther. 2017;7:S77&#x2013;S81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5509921</ArticleId><ArticleId IdType="pubmed">28748153</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SJ, Ahn JM, Kim YH, Park DW, Yun SC, Lee JY, Kang SJ, Lee SW, Lee CW, Park SW, Choo SJ, Chung CH, Lee JW, Cohen DJ, Yeung AC, Hur SH, Seung KB, Ahn TH, Kwon HM, Lim DS, Rha SW, Jeong MH, Lee BK, Tresukosol D, Fu GS, Ong TK BEST Trial Investigators. Trial of everolimus-eluting stents or bypass surgery for coronary disease. N Engl J Med. 2015;372:1204&#x2013;1212.</Citation><ArticleIdList><ArticleId IdType="pubmed">25774645</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Q, Huang J, Zhu K, Chen Q. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with coronary heart disease and type 2 diabetes mellitus: Cumulative meta-analysis. Clin Cardiol. 2021;44:899&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8259162</ArticleId><ArticleId IdType="pubmed">34089266</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan A, Ishfaq L, Wolbert P, Darapaneni H, Khetarpal V, Sahu S, Farooq W. C-70 | Comparative Outcomes of Left Main PCI vs. CABG: A Meta-Analysis of Mortality, Revascularization, and Quality of Life. J Soc Cardiovasc Angiogr Interv. 2025;4:103060.</Citation></Reference><Reference><Citation>Shah T, Geleris JD, Zhong M, Swaminathan RV, Kim LK, Feldman DN. Fractional flow reserve to guide surgical coronary revascularization. J Thorac Dis. 2017;9:S317&#x2013;S326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5422666</ArticleId><ArticleId IdType="pubmed">28540075</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhat S, Yatsynovich Y, Sharma UC. Coronary revascularization in patients with stable coronary disease and diabetes mellitus. Diab Vasc Dis Res. 2021;18:14791641211002469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8482730</ArticleId><ArticleId IdType="pubmed">33926268</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang SJ, Lee CW, Song H, Ahn JM, Kim WJ, Lee JY, Park DW, Lee SW, Kim YH, Mintz GS, Park SW, Park SJ. OCT analysis in patients with very late stent thrombosis. JACC Cardiovasc Imaging. 2013;6:695&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pubmed">23643282</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanini GG, Holmes DR Jr. Drug-eluting coronary-artery stents. N Engl J Med. 2013;368:254&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">23323902</ArticleId></ArticleIdList></Reference><Reference><Citation>Xaplanteris P, Fournier S, Pijls NHJ, Fearon WF, Barbato E, Tonino PAL, Engstr&#xf8;m T, K&#xe4;&#xe4;b S, Dambrink JH, Rioufol G, Toth GG, Piroth Z, Witt N, Fr&#xf6;bert O, Kala P, Linke A, Jagic N, Mates M, Mavromatis K, Samady H, Irimpen A, Oldroyd K, Campo G, Rothenb&#xfc;hler M, J&#xfc;ni P, De Bruyne B FAME 2 Investigators. Five-Year Outcomes with PCI Guided by Fractional Flow Reserve. N Engl J Med. 2018;379:250&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">29785878</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfonso F, Byrne RA, Rivero F, Kastrati A. Current treatment of in-stent restenosis. J Am Coll Cardiol. 2014;63:2659&#x2013;2673.</Citation><ArticleIdList><ArticleId IdType="pubmed">24632282</ArticleId></ArticleIdList></Reference><Reference><Citation>Farooq V, Serruys PW, Bourantas CV, Zhang Y, Muramatsu T, Feldman T, Holmes DR, Mack M, Morice MC, St&#xe5;hle E, Colombo A, de Vries T, Morel MA, Dawkins KD, Kappetein AP, Mohr FW. Quantification of incomplete revascularization and its association with five-year mortality in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial validation of the residual SYNTAX score. Circulation. 2013;128:141&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pubmed">23766350</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunn J, Taggart DP. Revascularisation for acute coronary syndromes: PCI or CABG? Heart. 2003;89:967&#x2013;970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1767806</ArticleId><ArticleId IdType="pubmed">12922989</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">41018697</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2328-8957</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Open forum infectious diseases</Title><ISOAbbreviation>Open Forum Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Early versus deferred antiretroviral therapy initiation and long-term cardiovascular disease outcomes in people with HIV: The START study.</ArticleTitle><Pagination><StartPage>ofaf561</StartPage><MedlinePgn>ofaf561</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ofaf561</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ofid/ofaf561</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">It is unknown whether delayed antiretroviral therapy (ART) initiation worsens CVD outcomes in people with HIV (PHIV). This study compared CVD event rates between PHIV who were randomized to receive immediate versus deferred ART.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">ART-na&#xef;ve adult PHIV with CD4+ counts &gt; 500 cells/&#xb5;L were randomized to immediate versus deferred ART initiation. Event rates for the main composite CVD outcome (myocardial infarction, coronary artery disease requiring revascularization, stroke and CVD-related death) were estimated for: (i) pre-2016 (treatment arms as designed); (ii) post-1Jan2016 (ART use similar across arms); and (iii) entire study follow-up period. Subgroup analyses were performed according to baseline characteristics.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Among 4684 participants (median age 36 years, 27% female, 30% Black race), 32% were smokers and 17% had a BMI &#x2265; 30&#x2005;kg/m<sup>2</sup>. Comorbidities included hypertension (19%), dyslipidemia (8%), diabetes (3%); 0.8% had a history of CVD. The median time to ART initiation was 2.5 years (interquartile range [IQR] 1.6-3.5 years) in the deferred arm and 7 days (IQR 2-17 days) in the immediate arm. Over the entire study follow-up period (median follow-up of 9.3 years), 71 participants (35 immediate, 36 deferred) experienced a CVD event with no difference in CVD event rates between the immediate and deferred arms (0.17 vs 0.17 per 100 person-years, respectively); these findings were consistent across the pre-2016 and post-1Jan2016 periods. There were 58 CVD events among males (33 immediate; 25 deferred) and 13 among females (2 immediate; 11 deferred). A possible benefit of immediate ART was seen in females but not males (Hazard Ratio = 0.19 [95% confidence interval: 0.04-0.86] vs 1.33 [0.79-2.24]; interaction <i>P</i>-value = .014), though numbers of events were low.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Early versus deferred ART initiation was not associated with reduced CVD events. The potential benefit associated with immediate ART in female participants warrants further evaluation.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dharan</LastName><ForeName>Nila J</ForeName><Initials>NJ</Initials><Identifier Source="ORCID">0000-0003-1175-5962</Identifier><AffiliationInfo><Affiliation>Therapeutic and Vaccine Research Program, Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Shweta</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Biostatistics and Health Data Science, University of Minnesota, Minneapolis Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arenas-Pinto</LastName><ForeName>Alejandro</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3368-5005</Identifier><AffiliationInfo><Affiliation>MRC Clinical Trials Unit, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Global Health, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duprez</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-0993-6839</Identifier><AffiliationInfo><Affiliation>Cardiovascular Division, Department Medicine, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Estrada</LastName><ForeName>Vicente</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Hospital Clinico San Carlos, IdiSSC, CiberInfec, Universidad Complutense, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ha</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Cooper University Health Care, Cooper Medical School of Rowan University, Camden, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Angelica Kundro</LastName><ForeName>Mariana</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Emerging Diseases, JM Ramos Mejia Hospital, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mngqibisa</LastName><ForeName>Rosie</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-6540-5733</Identifier><AffiliationInfo><Affiliation>Durban International Clinical Research Site, King Edward Hospital, Enhancing Care Foundation, Durban, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mugerwa</LastName><ForeName>Henry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Joint Clinical Research Centre, Kampala, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munroe</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>INSIGHT Community Advisory Board, Coordinating Centers for BioMedical Research (CCBR), University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nasreddine</LastName><ForeName>Rakan</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-1265-1500</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Saint-Pierre University Hospital, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peterson</LastName><ForeName>Tess E</ForeName><Initials>TE</Initials><Identifier Source="ORCID">0000-0002-7223-651X</Identifier><AffiliationInfo><Affiliation>Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sereti</LastName><ForeName>Irini</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-0076-0224</Identifier><AffiliationInfo><Affiliation>Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trevillyan</LastName><ForeName>Janine M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-8660-5558</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Austin Health, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases University of Melbourne at the Peter Doherty Institute of Infection and Immunity, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Jason V</ForeName><Initials>JV</Initials><Identifier Source="ORCID">0000-0002-5542-1545</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matthews</LastName><ForeName>Gail V</ForeName><Initials>GV</Initials><AffiliationInfo><Affiliation>Therapeutic and Vaccine Research Program, Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phillips</LastName><ForeName>Andrew N</ForeName><Initials>AN</Initials><Identifier Source="ORCID">0000-0003-2384-4807</Identifier><AffiliationInfo><Affiliation>Institute for Global Health, University College London, London &#xa0;UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Open Forum Infect Dis</MedlineTA><NlmUniqueID>101637045</NlmUniqueID><ISSNLinking>2328-8957</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HIV</Keyword><Keyword MajorTopicYN="N">antiretroviral therapy</Keyword><Keyword MajorTopicYN="N">cardiovascular disease</Keyword></KeywordList><CoiStatement>Potential conflicts of interest. N. J. D. has received research support through the Gilead Australia Fellowship for an unrelated project. A. A.&#x2013;P. reports grants to his institution from Janssen, ViiV Healthcare and Gilead Sciences for unrelated projects, and advisory board fees from ViiV Healthcare. V. E. has received financial support from Gilead, ViiV and Johnson &amp; Johnson Innovative Medicines. I. S. holds United States Patent No. US 10001483B2, Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds and uses of biomarkers. I. S. has collaborative research agreements with NeoImmunoTech and with Karius under her official NIAID duties. The work of I. S. on this project was supported by the intramural research program of NIAID/NIH. J. M. T.'s institution has received funding from ViiV Healthcare, Gilead Health Sciences, Moderna and CSL Seqirus for speaking responsibilities and advisory board contributions. G. V. M. has received grants from ViiV Healthcare and Janssen, has served on the Advisory Board for Viiv and has received speaker's fee from Gilead Sciences. A. N. P. has received consultancy fees from the World Health Organization. None of the other authors have any conflicts of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>29</Day><Hour>13</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>29</Day><Hour>13</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41018697</ArticleId><ArticleId IdType="pmc">PMC12461870</ArticleId><ArticleId IdType="doi">10.1093/ofid/ofaf561</ArticleId><ArticleId IdType="pii">ofaf561</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>INSIGHT START Study Group, Lundgren &#xa0;JD, Babiker &#xa0;AG, et al. &#xa0;Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med &#xa0;2015; 373:795&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4569751</ArticleId><ArticleId IdType="pubmed">26192873</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcus &#xa0;JL, Leyden &#xa0;WA, Alexeeff &#xa0;SE, et al. &#xa0;Comparison of overall and comorbidity-free life expectancy between insured adults with and without HIV infection, 2000&#x2013;2016. JAMA Netw Open &#xa0;2020; 3:e207954.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7296391</ArticleId><ArticleId IdType="pubmed">32539152</ArticleId></ArticleIdList></Reference><Reference><Citation>So-Armah &#xa0;K, Benjamin &#xa0;LA, Bloomfield &#xa0;GS, et al. &#xa0;HIV and cardiovascular disease. Lancet HIV &#xa0;2020; 7:e279&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9346572</ArticleId><ArticleId IdType="pubmed">32243826</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah &#xa0;ASV, Stelzle &#xa0;D, Lee &#xa0;KK, et al. &#xa0;Global burden of atherosclerotic cardiovascular disease in people living with HIV. Circulation &#xa0;2018; 138:1100&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6221183</ArticleId><ArticleId IdType="pubmed">29967196</ArticleId></ArticleIdList></Reference><Reference><Citation>Gooden &#xa0;TE, Gardner &#xa0;M, Wang &#xa0;J, et al. &#xa0;Incidence of cardiometabolic diseases in people with and without human immunodeficiency virus in the United Kingdom: a population-based matched cohort study. J Infect Dis &#xa0;2022; 225:1348&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9016421</ArticleId><ArticleId IdType="pubmed">34417792</ArticleId></ArticleIdList></Reference><Reference><Citation>Grand &#xa0;M, Bia &#xa0;D, Diaz &#xa0;A. Cardiovascular risk assessment in people living with HIV: a systematic review and meta-analysis of real-life data. Curr HIV Res &#xa0;2020; 18:5&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">31830884</ArticleId></ArticleIdList></Reference><Reference><Citation>van Zoest &#xa0;RA, Wit &#xa0;FW, Kooij &#xa0;KW, et al. &#xa0;Higher prevalence of hypertension in HIV-1-infected patients on combination antiretroviral therapy is associated with changes in body composition and prior stavudine exposure. Clin Infect Dis &#xa0;2016; 63:205&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">27143668</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz &#xa0;P, Ferketich &#xa0;A. Smoking and HIV: confronting the epidemic. Lancet HIV &#xa0;2018; 5:e109&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">29329762</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy &#xa0;KP, Parker &#xa0;RA, Losina &#xa0;E, et al. &#xa0;Impact of cigarette smoking and smoking cessation on life expectancy among people with HIV: a US-based modeling study. J Infect Dis &#xa0;2016; 214:1672&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5144729</ArticleId><ArticleId IdType="pubmed">27815384</ArticleId></ArticleIdList></Reference><Reference><Citation>Petoumenos &#xa0;K, Worm &#xa0;S, Reiss &#xa0;P, et al. &#xa0;Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study(*). HIV Med &#xa0;2011; 12:412&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3070963</ArticleId><ArticleId IdType="pubmed">21251183</ArticleId></ArticleIdList></Reference><Reference><Citation>De Socio &#xa0;GV, Ricci &#xa0;E, Piconi &#xa0;S, et al. &#xa0;Impact of smoking habits on cardiovascular and neoplastic events and all-cause death in people with HIV from the STOPSHIV cohort. AIDS &#xa0;2025; 39:143&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">39434586</ArticleId></ArticleIdList></Reference><Reference><Citation>Elvstam &#xa0;O, Marrone &#xa0;G, Engstrom &#xa0;G, et al. &#xa0;Associations between HIV viremia during antiretroviral therapy and cardiovascular disease. AIDS &#xa0;2022; 36:1829&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">35730359</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker &#xa0;J, Quick &#xa0;H, Hullsiek &#xa0;KH, et al. &#xa0;Interleukin-6 and d-dimer levels are associated with vascular dysfunction in patients with untreated HIV infection. HIV Med &#xa0;2010; 11:608&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2942962</ArticleId><ArticleId IdType="pubmed">20456504</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann &#xa0;U, Lu &#xa0;MT, Foldyna &#xa0;B, et al. &#xa0;Assessment of coronary artery disease with computed tomography angiography and inflammatory and immune activation biomarkers among adults with HIV eligible for primary cardiovascular prevention. JAMA Netw Open &#xa0;2021; 4:e2114923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8243232</ArticleId><ArticleId IdType="pubmed">34185068</ArticleId></ArticleIdList></Reference><Reference><Citation>Dharan &#xa0;NJ, Yeh &#xa0;P, Bloch &#xa0;M, et al. &#xa0;HIV is associated with an increased risk of age-related clonal hematopoiesis among older adults. Nat Med &#xa0;2021; 27:1006&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">34099923</ArticleId></ArticleIdList></Reference><Reference><Citation>Kooij &#xa0;KW, Schouten &#xa0;J, Wit &#xa0;FW, et al. &#xa0;Difference in aortic stiffness between treated middle-aged HIV type 1-infected and uninfected individuals largely explained by traditional cardiovascular risk factors, with an additional contribution of prior advanced immunodeficiency. J Acquir Immune Defic Syndr &#xa0;2016; 73:55&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">27513572</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabin &#xa0;CA, Ryom &#xa0;L, De Wit &#xa0;S, et al. &#xa0;Associations between immune depression and cardiovascular events in HIV infection. AIDS &#xa0;2013; 27:2735&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">23842128</ArticleId></ArticleIdList></Reference><Reference><Citation>Triant &#xa0;VA, Regan &#xa0;S, Lee &#xa0;H, Sax &#xa0;PE, Meigs &#xa0;JB, Grinspoon &#xa0;SK. Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. J Acquir Immune Defic Syndr &#xa0;2010; 55:615&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3036774</ArticleId><ArticleId IdType="pubmed">20827215</ArticleId></ArticleIdList></Reference><Reference><Citation>Drozd &#xa0;DR, Kitahata &#xa0;MM, Althoff &#xa0;KN, et al. &#xa0;Increased risk of myocardial infarction in HIV-infected individuals in North America compared with the general population. J Acquir Immune Defic Syndr &#xa0;2017; 75:568&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5522001</ArticleId><ArticleId IdType="pubmed">28520615</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos &#xa0;AG, Venter &#xa0;WDF. Cardiovascular toxicity of contemporary antiretroviral therapy. Curr Opin HIV AIDS &#xa0;2021; 16:286&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">34545036</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabin &#xa0;CA, Reiss &#xa0;P, Ryom &#xa0;L, et al. &#xa0;Is there continued evidence for an association between Abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. BMC Med &#xa0;2016; 14:61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815070</ArticleId><ArticleId IdType="pubmed">27036962</ArticleId></ArticleIdList></Reference><Reference><Citation>DAD Study Group, Friis-Moller &#xa0;N, Reiss &#xa0;P, et al. &#xa0;Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med &#xa0;2007; 356:1723&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">17460226</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker &#xa0;JV, Sharma &#xa0;S, Achhra &#xa0;AC, et al. &#xa0;Changes in cardiovascular disease risk factors with immediate versus deferred antiretroviral therapy initiation among HIV-positive participants in the START (strategic timing of antiretroviral treatment). Trial. J Am Heart Assoc &#xa0;2017; 6(5):e004987.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5524070</ArticleId><ArticleId IdType="pubmed">28533305</ArticleId></ArticleIdList></Reference><Reference><Citation>Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Available at: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf. Access date March 17, 2021.</Citation></Reference><Reference><Citation>Achhra &#xa0;AC, Mocroft &#xa0;A, Reiss &#xa0;P, et al. &#xa0;Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. HIV Med &#xa0;2016; 17:255&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">26216031</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundgren &#xa0;JD, Babiker &#xa0;AG, Sharma &#xa0;S, et al. &#xa0;Long-term benefits from early antiretroviral therapy initiation in HIV infection. NEJM Evid &#xa0;2023; 2(3).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10194271</ArticleId><ArticleId IdType="pubmed">37213438</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson &#xa0;KM, Odell &#xa0;PM, Wilson &#xa0;PW, Kannel &#xa0;WB. Cardiovascular disease risk profiles. Am Heart J &#xa0;1991; 121(1 Pt 2):293&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1985385</ArticleId></ArticleIdList></Reference><Reference><Citation>Goff &#xa0;DC &#xa0;Jr, Lloyd-Jones &#xa0;DM, Bennett &#xa0;G, et al. &#xa0;2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation &#xa0;2014; 129(25 Suppl 2):S49&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">24222018</ArticleId></ArticleIdList></Reference><Reference><Citation>Guaraldi &#xa0;G, Orlando &#xa0;G, Zona &#xa0;S, et al. &#xa0;Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis &#xa0;2011; 53:1120&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">21998278</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips &#xa0;AN, Neaton &#xa0;J, Lundgren &#xa0;JD. The role of HIV in serious diseases other than AIDS. AIDS &#xa0;2008; 22:2409&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2679976</ArticleId><ArticleId IdType="pubmed">19005264</ArticleId></ArticleIdList></Reference><Reference><Citation>Leierer &#xa0;G, Rieger &#xa0;A, Schmied &#xa0;B, et al. &#xa0;A lower CD4 count predicts most causes of death except cardiovascular deaths. The Austrian HIV cohort study. Int J Environ Res Public Health &#xa0;2021; 18:12532.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8656512</ArticleId><ArticleId IdType="pubmed">34886257</ArticleId></ArticleIdList></Reference><Reference><Citation>Borges &#xa0;AH, Neuhaus &#xa0;J, Sharma &#xa0;S, et al. &#xa0;The effect of interrupted/deferred antiretroviral therapy on disease risk: a SMART and START combined analysis. J Infect Dis &#xa0;2019; 219:254&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6306018</ArticleId><ArticleId IdType="pubmed">30032171</ArticleId></ArticleIdList></Reference><Reference><Citation>Abelman &#xa0;RA, Mugo &#xa0;BM, Zanni &#xa0;MV. Conceptualizing the risks of coronary heart disease and heart failure among people aging with HIV: sex-specific considerations. Curr Treat Options Cardiovasc Med &#xa0;2019; 21:41.</Citation><ArticleIdList><ArticleId IdType="pubmed">31309321</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Burden of Disease 2019 Stroke Collaborators . Global, regional, and national burden of stroke and its risk factors, 1990&#x2013;2019: a systematic analysis for the global burden of disease study 2019. Lancet Neurol &#xa0;2021; 20:795&#x2013;820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8443449</ArticleId><ArticleId IdType="pubmed">34487721</ArticleId></ArticleIdList></Reference><Reference><Citation>Kentoffio &#xa0;K, Temu &#xa0;TM, Shakil &#xa0;SS, Zanni &#xa0;MV, Longenecker &#xa0;CT. Cardiovascular disease risk in women living with HIV. Curr Opin HIV AIDS &#xa0;2022; 17:270&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9370828</ArticleId><ArticleId IdType="pubmed">35938460</ArticleId></ArticleIdList></Reference><Reference><Citation>Frazier &#xa0;EL, Sutton &#xa0;MY, Tie &#xa0;Y, Fagan &#xa0;J, Fanfair &#xa0;RN. Differences by sex in cardiovascular comorbid conditions among older adults (aged 50&#x2013;64 or &gt;/=65 years) receiving care for human immunodeficiency virus. Clin Infect Dis &#xa0;2019; 69:2091&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">31051034</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow &#xa0;FC, Regan &#xa0;S, Zanni &#xa0;MV, et al. &#xa0;Elevated ischemic stroke risk among women living with HIV infection. AIDS &#xa0;2018; 32:59&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5718937</ArticleId><ArticleId IdType="pubmed">28926405</ArticleId></ArticleIdList></Reference><Reference><Citation>Go &#xa0;AS, Reynolds &#xa0;K, Avula &#xa0;HR, et al. &#xa0;Human immunodeficiency virus infection and variation in heart failure risk by age, sex, and ethnicity: the HIV HEART study. Mayo Clin Proc &#xa0;2022; 97:465&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9074114</ArticleId><ArticleId IdType="pubmed">34916054</ArticleId></ArticleIdList></Reference><Reference><Citation>Siedner &#xa0;MJ, Zanni &#xa0;M, Tracy &#xa0;RP, et al. &#xa0;Increased systemic inflammation and gut permeability among women with treated HIV infection in rural Uganda. J Infect Dis &#xa0;2018; 218:922&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6093434</ArticleId><ArticleId IdType="pubmed">29718342</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanni &#xa0;MV, Foldyna &#xa0;B, McCallum &#xa0;S, et al. &#xa0;Sex differences in subclinical atherosclerosis and systemic immune activation/inflammation among people with human immunodeficiency virus in the United States. Clin Infect Dis &#xa0;2023; 76:323&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839188</ArticleId><ArticleId IdType="pubmed">36101518</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam &#xa0;JO, Leyden &#xa0;WA, Leong &#xa0;TK, et al. &#xa0;Variation in heart failure risk by HIV severity and sex in people with HIV infection. J Acquir Immune Defic Syndr &#xa0;2022; 91:175&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9471068</ArticleId><ArticleId IdType="pubmed">36094484</ArticleId></ArticleIdList></Reference><Reference><Citation>Elvstam &#xa0;O, Ryom &#xa0;L, Neesgaard &#xa0;B, et al. &#xa0;Viremia does not independently predict cardiovascular disease in people with HIV: a RESPOND cohort study. Open Forum Infect Dis &#xa0;2025; 12:ofaf016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11786055</ArticleId><ArticleId IdType="pubmed">39896984</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>